PolyPid (PYPD) 20-F 26 Feb 25 2024 FY Annual report (foreign) Financial data

Cover

Cover	12 Months Ended
	Dec. 31, 2024 shares
Document Information [Line Items]
Document Type	20-F
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Financial Statement Error Correction [Flag]	false
Document Shell Company Report	false
Entity Interactive Data Current	Yes
Document Accounting Standard	U.S. GAAP
ICFR Auditor Attestation Flag	false
Amendment Flag	false
Document Period End Date	Dec. 31, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Entity Information [Line Items]
Entity Registrant Name	POLYPID LTD.
Entity Central Index Key	0001611842
Entity File Number	001-38428
Entity Incorporation, State or Country Code	L3
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Incorporation, Date of Incorporation	Feb. 28, 2008
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	18 Hasivim Street
Entity Address, City or Town	Petach Tikva
Entity Address, Country	IL
Entity Address, Postal Zip Code	495376
Entity Listings [Line Items]
Title of 12(b) Security	Ordinary Shares, no par value
Trading Symbol	PYPD
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding	10,190,904
Business Contact [Member]
Entity Contact Personnel [Line Items]
Contact Personnel Name	Dikla Czaczkes Akselbrad
Entity Address, Address Line One	372 Franklin Ave.
Entity Address, Address Line Two	P.O. Box 558
Entity Address, City or Town	Nutley
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07110
Entity Phone Fax Numbers [Line Items]
City Area Code	(908)
Local Phone Number	858-5995

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2024
Auditor [Table]
Auditor Name	KOST FORER GABBAY & KASIERER
Auditor Firm ID	1281
Auditor Location	Haifa, Israel
Auditor Opinion [Text Block]	Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheets of PolyPid Ltd. and its subsidiaries (the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations, changes in shareholders’ equity (deficit) and cash flows for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 15,641	$ 5,309
Restricted deposits	168	300
Prepaid expenses and other current assets	764	458
Total current assets	16,573	6,067
LONG-TERM ASSETS:
Property and equipment, net	6,075	7,621
Operating lease right-of-use assets	2,295	1,597
Other long-term assets	277	87
Total long-term assets	8,647	9,305
Total assets	25,220	15,372
CURRENT LIABILITIES:
Trade payables	2,409	772
Accrued expenses and other current liabilities	2,566	1,971
Current maturities of long-term debt	6,787	4,003
Current maturities of operating lease liabilities	919	540
Total current liabilities	12,681	7,286
LONG-TERM LIABILITIES:
Long-term debt	634	6,379
Deferred revenues	2,548	2,548
Long-term operating lease liabilities	1,277	857
Other liabilities	396	398
Total long-term liabilities	4,855	10,182
COMMITMENTS AND CONTINGENT LIABILITIES (NOTE 8)
SHAREHOLDERS’ EQUITY (DEFICIT):
Ordinary shares, no par value - Authorized: 107,800,000 shares at December 31, 2024 and 2023, respectively; Issued and outstanding: 10,190,904 and 1,653,559 shares at December 31, 2024 and 2023, respectively
Additional paid-in capital	275,015	236,213
Accumulated deficit	(267,331)	(238,309)
Total shareholders’ equity (deficit)	7,684	(2,096)
Total liabilities and shareholders’ equity (deficit)	$ 25,220	$ 15,372

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Ordinary shares, par value (in Dollars per share)
Ordinary shares, authorized	107,800,000	107,800,000
Ordinary shares, issued	10,190,904	1,653,559
Ordinary shares, outstanding	10,190,904	1,653,559

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development, net		$ 22,811	$ 16,148	$ 27,990
Marketing and business development		945	1,196	2,888
General and administrative		4,273	5,523	8,010
Operating loss		28,029	22,867	38,888
Financial expense, net		951	929	540
Loss before income tax		28,980	23,796	39,428
Income tax expense		42	69	129
Net loss		$ 29,022	$ 23,865	$ 39,557
Basic (in Dollars per share)	[1]	$ 4.91	$ 16.99	$ 61.09
Diluted (in Dollars per share)	[1]	$ 4.91	$ 16.93	$ 61.09
Basic (in Shares)	[1]	5,912,890	1,404,368	647,556
Diluted (in Shares)	[1]	5,912,890	1,421,308	647,556
[1] Results for the year ended December 31, 2022, have been retroactively adjusted to reflect the 1-for-30 reverse share split affected on September 18, 2023 (see Note 1b).

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders’ Equity (Deficit) - USD ($) $ in Thousands		Number of Ordinary shares	Additional paid-in capital	Accumulated deficit	Total
Balance at Dec. 31, 2021			$ 210,847	$ (174,887)	$ 35,960
Balance (in Shares) at Dec. 31, 2021	[1]	633,093
Share-based compensation			4,307		4,307
Issuance of Ordinary shares, net	[2]		4,423		4,423
Issuance of Ordinary shares, net (in Shares)	[1],[2]	35,505
Issuance of warrants			588		588
Exercise of options			108		108
Exercise of options (in Shares)	[1]	1,007
Net loss				(39,557)	(39,557)
Balance at Dec. 31, 2022			220,273	(214,444)	5,829
Balance (in Shares) at Dec. 31, 2022	[1]	669,605
Share-based compensation			3,391		3,391
Issuance of pre-funded warrants, net	[3]		3,987		3,987
Modification of warrants			31		31
Reclassification of pre-funded warrants to Liabilities			(2,106)		(2,106)
Reclassification of pre-funded warrants to Equity			1,905		1,905
Cashless exercise of pre-funded warrants
Cashless exercise of pre-funded warrants (in Shares)		345,151
Issuance of Ordinary shares, net	[4]		8,723		8,723
Issuance of Ordinary shares, net (in Shares)	[4]	637,660
Exercise of options			9		9
Exercise of options (in Shares)		1,143
Net loss				(23,865)	(23,865)
Balance at Dec. 31, 2023			236,213	(238,309)	$ (2,096)
Balance (in Shares) at Dec. 31, 2023		1,653,559			1,653,559
Share-based compensation			2,824		$ 2,824
Issuance of Ordinary shares, warrants and pre-funded warrants, net	[5]		35,863		35,863
Issuance of Ordinary shares, warrants and pre-funded warrants, net (in Shares)	[5]	8,537,345
Issuance of warrants			115		115
Net loss				(29,022)	(29,022)
Balance at Dec. 31, 2024			$ 275,015	$ (267,331)	$ 7,684
Balance (in Shares) at Dec. 31, 2024		10,190,904			10,190,904
[1] Results for the year ended December 31, 2022, have been retroactively adjusted to reflect the 1-for-30 reverse share split affected on September 18, 2023 (see Note 1b). Net of issuance costs of $222. Net of issuance costs of $362. Net of issuance costs of $757. Net of issuance costs of $2,894.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (29,022)	$ (23,865)	$ (39,557)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	1,622	1,822	1,721
Remeasurement of warrants		(201)
Financial expenses, net	697	1,727	289
Share-based compensation expenses	2,824	3,391	4,307
Changes in assets and liabilities:
Prepaid expenses and other assets	(315)	641	1,185
Operating lease right-of-use assets	824	593	(2,431)
Operating lease liabilities	(723)	(494)	2,132
Trade payables	1,637	(369)	(3,095)
Deferred revenues			2,548
Accrued expenses and other liabilities	493	(481)	(1,416)
Net cash used in operating activities	(21,963)	(17,236)	(34,317)
Cash flows from investing activities:
Investment in bank deposits	(21,353)	(18,600)	(7,000)
Proceeds from bank deposits	21,099	22,600	25,342
Purchase of property and equipment	(76)	(196)	(1,767)
Net cash provided by investing activities	(330)	3,804	16,575
Cash flows from financing activities:
Proceeds from exercise of options		9	108
Proceeds from issuance of Ordinary shares, warrants and pre-funded warrants, net	35,863	12,710	5,011
Proceeds from long-term debt, net			11,711
Payment due to long-term debt	(3,322)	(2,618)	(402)
Payment of fees due to modification of debt	(125)	(125)
Net cash provided by financing activities	32,416	9,976	16,428
Increase (decrease) in cash, cash equivalents and restricted deposits	10,123	(3,456)	(1,314)
Cash, cash equivalents and restricted deposits at the beginning of the year	5,686	9,142	10,456
Cash, cash equivalents and restricted deposits at the end of the year	15,809	5,686	9,142
Supplemental disclosures of cash flows:
Interest paid	950	1,038	734
Cash paid during the year for income taxes	3	18	8
Supplemental disclosures of cash flow information:
Cash and cash equivalents	15,641	5,309	8,552
Restricted deposits	168	300	511
Restricted deposits included in other long-term assets		77	79
Cash, cash equivalents and restricted deposits at the end of the year	15,809	5,686	9,142
Supplemental disclosures of non-cash investing and financing information:
Property and equipment acquired by credit			100
Property and equipment paid for in prior periods			340
Right-of-use asset recognized with corresponding lease liability	1,522	241	3,528
Credit line derivative	100	127
Modification of warrants		31
Warrants issued as part of credit line	$ 115

General

General	12 Months Ended
	Dec. 31, 2024
General [Abstract]
GENERAL	NOTE 1:- GENERAL a. PolyPid Ltd. (the “Company”) was incorporated under the laws of Israel and commenced operations on February 28, 2008. The Company is a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. The Company’s product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients locally at predetermined release rates and durations over extended periods ranging from days to several months. The Company is initially focused on the development of its lead product candidate, D-PLEX 100 The Company’s wholly owned subsidiaries include a subsidiary in the United States of America (the “US Subsidiary”) and a subsidiary in Romania. The US Subsidiary’s operation focuses on marketing and business development of the Company’s operation in the United States of America. b. On September 18, 2023, the Company’s board of directors approved 1-for-30 reverse share split. No fractional shares were issued, and no cash or other consideration was paid as a result of the reverse share split. Instead, the Company issued one additional whole share of the post-reverse share split Ordinary share to any shareholder who otherwise would have received a fractional share as a result of the reverse share split. The amount of authorized Ordinary shares was not affected. All issued and outstanding share and per share amounts included in the accompanying consolidated financial statements have been adjusted to reflect this reverse share split for all periods presented. c. The Company’s activities since inception have consisted of performing research and development activities. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations is dependent on future events, including, among other things, its ability to secure financing; obtain marketing approval from regulatory authorities; access potential markets; build a sustainable customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. The Company’s operations are funded by its shareholders and research and development grants and the Company intends to seek further private or public financing as well as make applications for further research and development grants for continuing its operations. Although management believes that the Company will be able to successfully fund its operations, there can be no assurance that the Company will be able to do so or that the Company will ever operate profitably. In September 2022, the Company announced top-line results from the Surgical site Hospital acquired Infection prEvention with Local D-PLEX 100 100 That said, in a pre-specified subgroup ITT analysis requested by the United States (“U.S.”) Food and Drug Administration (“FDA”) of a total of 423 subjects with large incisions (>20 centimeters), the local administration of D-PLEX 100 100 In November 2022, the Company provided the FDA with available data from the SHIELD I study as part of a Type D meeting request. Following positive Type D meeting communication with the FDA, which took place in January 2023, on the SHIELD I Phase 3 data, the Company now has a clear regulatory pathway towards a potential new drug application (“NDA”) submission. Based on the data, particularly the 54% reduction observed in the primary endpoint in complex surgeries in a pre-specified subgroup analysis of patients with large open incisions (p=0.0032, n=423) compared to SoC, the FDA acknowledged that the SHIELD I results may provide supportive evidence on this population and recommended that the Company conduct an additional study to support a potential NDA submission. The FDA stated that the ongoing SHIELD II study could potentially serve as such a study. The FDA also recognized that D-PLEX 100 The Company resumed recruitment into the SHIELD II trial in June 2023. Unblinded interim analysis was conducted once the first 430 patients completed their 30-day follow-up. In December 2024, the Company announced that following the independent Data Safety Monitoring Board’s (“DSMB”) review of unblinded efficacy data from the first 430 enrolled patients, the DSMB’s recommendation was to conclude the study upon enrollment of 800 patients, which is the lowest sample size reassessment stop after the minimum planned number of 624 patients. The Company expects to continue to incur substantial losses over the next several years during its clinical development phase. To fully execute its business plan, the Company will need to complete phase 3 clinical studies and certain development activities as well as manufacture the required clinical and commercial production batches in the pilot manufacturing plant. Further, the Company’s product candidates will require regulatory approval prior to commercialization and the Company will need to establish sales, marketing and logistic infrastructures. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. As of December 31, 2024, the Company had cash and cash equivalents in the total amount of $15,641. During the year ended December 31, 2024, the Company incurred a net loss of $29,022 and had negative cash flows from operating activities of $21,963. In addition, the Company had an accumulated deficit of $267,331 at December 31, 2024. The Company’s future operations are highly dependent on a combination of factors, including (i) completion of all required clinical studies; (ii) the success of its research and development activities; (iii) manufacture of all required clinical and commercial production batches; (iv) marketing approval by the relevant regulatory authorities; and (v) market acceptance of the Company’s product candidates. There can be no assurance that the Company will succeed in achieving the clinical, scientific and commercial milestones as detailed above. Based on the abovementioned, as of the approval date of these consolidated financial statements, the Company has not raised the necessary funding in order to continue its activity for a period of at least one year after the date of the filing of this annual report on Form 20-F. The Company believes that the current cash balance will be sufficient to fund operations into the third quarter of 2025. Therefore, these factors raise a substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that might result should the Company be unable to continue as a going concern.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2024
Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES The consolidated financial statements are prepared according to United States generally accepted accounting principles (“U.S. GAAP”). a. Use of estimates: The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. b. Consolidated financial statements in U.S. dollars: The accompanying consolidated financial statements have been prepared in United States of America dollars (“$” or “U.S. dollars”). A substantial portion of the Company’s expenses are incurred in New Israeli Shekels (“NIS”). However, the Company finances its operations mainly in U.S. dollars, a substantial portion of its expenses are incurred in U.S. dollars and potential revenues from its primary markets are anticipated to be generated in U.S. dollars. As such, the Company’s management believes that the U.S. dollar is the currency of the primary economic environment in which the Company and its subsidiaries operate. Thus, the functional and reporting currency of the Company is the U.S. dollar. Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the dollar are re-measured into U.S. dollars in accordance with Accounting Standards Codification (“ASC”) No. 830, “ Foreign Currency Matters c. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances have been eliminated upon consolidation. d. Cash equivalents: Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three months or less, at the date acquired. e. Restricted deposits: Restricted cash is primarily invested in a bank deposit and is used as security for the Company’s lease commitments and for its forward and options transactions activities (see Note 2p). f. Segment reporting: The Company identifies operating segments in accordance with ASC No. 280, “Segment Reporting”, as components of an entity for which discrete financial information is available and is regularly reviewed by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and evaluating financial performance. The Company’s chief operating decision maker (“CODM”) is its chief executive officer, who manages the Company’s business activities as a single operating and reportable segment on a consolidated basis. Accordingly, the CODM uses consolidated net loss to assess financial performance and allocate resources. The CODM reviews and utilizes functional expenses (research and development, sales and marketing, and general and administrative) at the consolidated level as presented in the Company’s consolidated statements of operations, to manage the Company’s operations. Other financial information regarding the Company’s operating segment is presented elsewhere in consolidated financial statements. g. Short-term deposits: A short-term bank deposit is a deposit with a maturity of more than three months, but less than one year. Short-term deposits are presented at cost, which approximates market value due to their short maturities. h. Property and equipment, net: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers and software 33 Laboratory equipment 10 - 15 Furniture and office equipment 15 Leasehold improvements Over the shorter of the term of the lease or its useful life i. Leases: The Company adopted ASC No. 842, “ Leases Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably certain to be exercised, the lease term is for a major part of the remaining useful life of the asset, the present value of the lease payments equals or exceeds substantially all of the fair value of the asset, or the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if it does not meet any one of these criteria. Since all of the Company’s lease contracts do not meet any of the criteria above, the Company concluded that all of its lease contracts should be classified as operating leases. Right-of-use (“ROU”) assets and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on information available on the commencement date in determining the present value of lease payments. All ROU assets are reviewed for impairment. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. The Company also elected the practical expedient to not separate lease and non-lease components for its leases. The Company elected to not recognize a lease liability and a ROU asset for lease with a term of twelve j. Impairment of long-lived assets: The Company’s long-lived assets are reviewed for impairment in accordance with ASC No. 360, “ Property, Plant and Equipment As of December 31, 2024 and 2023, no impairment losses have been identified. k. Research and development, net expenses: Research and development expenses consist of personnel costs (including salaries, benefits and share-based compensation), materials, consulting fees and payments to subcontractors, chemical, manufacturing and control activities, costs associated with obtaining regulatory approvals, executing pre-clinical and clinical studies and maintenance and prosecution of the Company’s intellectual property rights. In addition, research and development expenses include overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development expenses as expenses when incurred and are presented net of government grants (see Note 2l). l. Grants and participations: Royalty-bearing grants from the Israeli Innovation Authority (“IIA”) of the Ministry of Economy and Industry in Israel for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and development expenses. Non-royalty-bearing grants from the IIA MAGNET program and from European Commission’s Seventh Framework Programme for Research (“FP7”) for funding approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and development expenses. Since the payment of royalties is not probable when the grants are received, the Company does not record a liability for amounts received from IIA until the related revenues are recognized. In the event of failure of a project that was partly financed by IIA, the Company will not be obligated to pay any royalties or repay the amounts received. The Company recognizes participations in research and development, as a reduction from research and development expenses in the amount of $0, $83 and $738 for the years ended December 31, 2024, 2023, and 2022, respectively. From inception up until December 31, 2024, the Company received a total of $7,290 in grants, out of which royalty-bearing grants in the amount of $4,888 from the IIA, non-royalty bearing grants in the amount of $1,675 from the IIA and non-royalty bearing grants in the amount of $727 from the FP7. m. Accounting for share-based compensation: Share-based compensation expense related to share-based awards is recognized based on the fair value of the awards granted and recognized as an expense on a straight-line basis over the requisite service period for share options. The fair value of each option award is estimated on the grant date using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including the expected term of the award, the expected volatility of the price of the Company’s Ordinary shares, risk-free interest rates, and the expected dividend yield of Ordinary shares. The assumptions used to determine the fair value of the share awards represent management’s best estimates. These estimates involve inherent uncertainties and the application of management’s judgment. Forfeitures are accounted for as they occur instead of estimating the number of awards expected to be forfeited. n. Basic and diluted net loss per share: The Company’s basic net loss per share is calculated by dividing the net loss attributable to Ordinary shareholders by the weighted-average number of shares of Ordinary shares outstanding for the period, without consideration of potentially dilutive securities. The diluted net loss per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method or the if-converted method based on the nature of such securities. Diluted net loss per share is the same as basic net loss per share in periods when the effects of potentially dilutive shares of Ordinary shares are anti-dilutive. o. Fair value of financial instruments: The Company applies ASC No. 820, “ Fair Value Measurements and Disclosures Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. Fair value is an exit price, representing the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value: Level 1 - Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities. Level 2 - Include other inputs that are directly or indirectly observable in the marketplace. Level 3 - Unobservable inputs which are supported by little or no market activity The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value . The carrying amounts of cash and cash equivalents, restricted deposits, prepaid expenses and other current assets, other long term assets, trade payables, accrued expenses and other current and non-current liabilities approximate their fair value due to the short-term maturity of such instruments. The fair value measurement of the Financial Component Asset (“FCA”) is measured using unobservable inputs that require a high level of judgment to determine fair value, and thus is classified as a Level 3 financial instrument. The Company estimates the fair value of the abovementioned instrument using the Monte-Carlo simulation and the Black-Scholes option pricing model. Fair value estimates are made at a specific point in time, based on relevant market information and information about the financial instruments. These estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect these estimates. p. Derivative financial instruments: The Company accounts for derivatives based on ASC 815. ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. The Company enters into option and forward contracts in order to limit the exposure to exchange rate fluctuation associated with expenses mainly incurred in NIS. Since the derivative instruments that the Company holds were not designated as hedging instruments under ASC 815, any gain or loss derived from such instruments is recognized immediately as “financial expense, net”. The Company measured the fair value of the contracts in accordance with ASC 820. Foreign currency derivative contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. As of December 31, 2024 and 2023, the fair value of the options and forward contracts was $0. Financial expense (income) for the years ended December 31, 2024, 2023 and 2022, amounted to $(19), $75 and 273, respectively. q. Income taxes: The Company accounts for income taxes in accordance with ASC No. 740, “ Income Taxes ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2024 and 2023, the Company’s uncertain tax position liability was $208 and $170, respectively. The Company’s policy is to accrue interest and penalties related to unrecognized tax benefits in its taxes on income. r. Revenue recognition: The Company recognizes revenue from contracts with customers under ASC No. 606, “ Revenue from Contracts with Customers To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assesses whether each good or service is distinct to determine the performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. On August 2, 2022, the Company entered into a license, distribution and supply agreement (the “Agreement”) with Mercury Pharma Group Limited, under the trade name Advanz Pharma Holdings (the “Customer”), with respect to the Company’s product, the D-PLEX 100 The term of the Agreement is until the later of December 31, 2035, or 10 years after the first commercial sale of the Product. The Agreement can also be terminated by either party under certain limited circumstances. Pursuant to the Agreement, the Customer was granted an exclusive license to market, commercialize, and distribute the Product in the European Economic Area and in the United Kingdom. Under the Agreement, the Company will carry out all activities required to obtain marketing authorization in each territory, approving the commercial sale of the Product in that territory. Once marketing authorization will be granted in a territory, the Customer will be required to achieve minimum sales requirements for that territory. Under the terms of the Agreement, the Company received a non-refundable, one-time payment of €2.5 million (approximately $2,548). The Company is also entitled to receive additional development-related milestones payments for a total of up to €23 million. In addition, the Company will be entitled to receive up to additional €87 million upon achievement of certain commercial sale milestones. The Company has concluded that the Agreement includes a single performance obligation. The Company has concluded that the license and development are not distinct from the manufacturing since the Customer could not use, consume, or sell the license and development services on their own or with resources readily available to the Customer because of the Company’s specialized knowledge and the associated manufacturing know-how and because currently, and in the foreseeable future, there are no other parties that could manufacture the Product. As such, the transaction price was fully allocated to the single performance obligation. Since it is not probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the milestone payments is resolved, the Company estimated the transaction price at €2.5 million (approximately $2,548). As of December 31, 2024, the Company has yet to satisfy its performance obligation under the Agreement and, therefore, no revenues were recognized. Accordingly, the upfront payment amount was classified as a long-term deferred revenue in the Company’s consolidated balance sheet as of December 31, 2024. s. Concentration of credit risks: Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and restricted deposits. Cash, cash equivalents and restricted deposits are deposited in major banks in Israel and in the United States of America. Such investments may be in excess of insured limits or not insured. Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal risk. The Company utilizes option and forward contracts to protect against the risk of overall changes in exchange rates. The derivative instruments hedge a portion of the Company’s non-dollar currency exposure. Counterparties to the Company’s derivative instruments are all major financial institutions. t. Severance pay: All the Company’s employees who are Israeli citizens have subscribed to Section 14 of Israel’s Severance Pay Law, 5723-1963 (“Section 14”). Pursuant to Section 14, employees covered by this section are entitled to monthly deposits at a rate of 8.33% of their monthly salary, made on their behalf by the Company. Payments in accordance with Section 14 release the Company from any future severance liabilities in respect of those employees. Neither severance pay liability nor severance pay fund under Section 14 for such employees is recorded on the Company’s consolidated balance sheets. Severance pay expense for the years ended December 31, 2024, 2023 and 2022, amounted to $404, $401 and $537, respectively. The US Subsidiary has a Safe Harbor 401(k) plan covering all the US Subsidiary employees. All eligible employees may elect to contribute up to 100% of their payroll compensation (minus mandatory payroll deductions) to the plan, for 2024, up to a maximum of $23 per year (for employees over 50 years of age the maximum contribution was $31 per year), as determined by the U.S. Internal Revenue Service (“IRS”). The US Subsidiary matches at 100%, on each payroll, up to 5% of the employee compensation to the plan within the IRS limits (which was set at $345 in 2024 for purposes of the plan). u. Contingent liabilities: The Company accounts for its contingent liabilities in accordance with ASC No. 450, “ Contingencies With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. The Company is occasionally a party to routine claims or litigation incidental to its business. The Company does not believe that it is a party to any pending legal proceeding that is likely to have a material adverse effect on its business, financial condition or results of operations. The Company recorded an accrual in the consolidated statement of operations, which it deems appropriate. As of December 31, 2024 and 2023, no liability due to legal matters has been accrued. v. Recently adopted accounting pronouncements: As an “Emerging Growth Company”, the Jumpstart Our Business Startups Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election. In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures”, which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted ASU 2023-07 during the year ended December 31, 2024. w. Recently issued accounting pronouncements, not yet adopted: In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company for fiscal years beginning after December 15, 2025, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09. In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2024
Prepaid Expenses and Other Current Assets [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	NOTE 3:- PREPAID EXPENSES AND OTHER CURRENT ASSETS December 31, 2024 2023 Prepaid expenses $ 330 $ 352 Government authorities 166 96 Other current assets 268 10 $ 764 $ 458

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2024
Property and Equipment, Net [Abstract]
PROPERTY AND EQUIPMENT, NET	NOTE 4:- PROPERTY AND EQUIPMENT, NET December 31, 2024 2023 Cost: Computers and software $ 630 $ 620 Laboratory equipment 8,167 8,122 Furniture and office equipment 173 173 Leasehold improvements 6,524 6,503 15,494 15,418 Less - Accumulated depreciation (9,419 ) (7,797 ) Depreciated cost $ 6,075 $ 7,621 Depreciation expenses amounted to $1,622, $1,822 and $1,721 for the years ended December 31, 2024, 2023 and 2022, respectively. The majority of the Company’s property and equipment is located in Israel.

Leases

Leases	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
LEASES	NOTE 5:- LEASES a. The Company’s facilities are leased under operating lease agreements for periods ending no later than 2027. On January 14, 2024, the Company entered into a new lease agreement for one of its premises, with the lease term extending through July 2027. The Company does not assume renewals in its determination of the lease term unless the renewals are deemed to be reasonably certain. Lease payments included in the measurement of the lease liability comprise the following: the fixed non-cancelable lease payments, payments for optional renewal periods, where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early. The Company has bank guarantees in connection with the facilities lease agreements in the total amount of $257. Accordingly, cash, in the same amount, was restricted in bank deposits. The Company also leases motor vehicles under various operating leases, the latest of which expires in 2027. b. The weighted average remaining lease term as of December 31, 2024, is 2.50 years. Weighted average discount rate is 10.40%. c. The components of operating lease expense for the year ended December 31, 2024, were $1,042. d. Lease liability as of December 31, 2024, is as follows: 2025 $ 999 2026 966 2027 484 Total undiscounted lease payments 2,449 Less - imputed interest (253 ) Present value of lease liabilities $ 2,196 e. The following table presents supplemental cash flow information related to the lease costs for operating leases as of December 31, 2024: Cash paid for amounts included in measurement of lease liability: Operating cash flows for operating leases $ 900 ROU asset recognized with corresponding lease liability: Operating leases $ 1,522

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2024
Accrued Expenses and Other Current Liabilities [Abstract]
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	NOTE 6:- ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES December 31, 2024 2023 Accrued expenses $ 1,464 $ 995 Employees and payroll accruals 1,079 958 Other liabilities 23 18 $ 2,566 $ 1,971

Line of Credit Arrangement

Line of Credit Arrangement	12 Months Ended
	Dec. 31, 2024
Line of Credit Arrangement [Abstract]
LINE OF CREDIT ARRANGEMENT	NOTE 7:- LINE OF CREDIT ARRANGEMENT On April 5, 2022, the Company entered into a secured line of credit agreement for up to $15,000 (the “Credit Line”) with Kreos Capital VI (Expert Fund) LP (“Kreos”). The Credit Line is comprised of three tranches in the amount of $10,000, $2,500 and $2,500, respectively, in which the first tranche and in the amount of $10,000 (the “First Tranche”) and the second tranche in the amount of $2,500 (the “Second Tranche) were drawn on April 26, 2022 and July 19, 2022, respectively. In addition, in accordance with the Credit Line agreement, the Company will issue to Kreos warrants to purchase the Company’s Ordinary shares equal to 8% of the amount of each tranche, when and if borrowed, with an exercise price of $154.05 per share. The expiration date for each warrant issued will be seven years from the agreement date. Accordingly, as a result of the First Tranche and Second Tranche withdrawal, the Company issued to Kreos warrants to purchase 6,491 Ordinary shares of the Company, at an exercise price of $154.05 per share. On each drawdown date, the Company shall pay to Kreos on the drawdown date the last period payment for such drawdown. For the First Tranche and Second Tranche, the amount the Company paid was $317 and $85, respectively. The third and final tranche of $2,500 will never be drawn since the third tranche milestone has not been met. The Company has concluded that the Credit Line includes several legally detachable and separately exercisable freestanding financial instruments: The First Tranche term loan, the warrants, and the right to receive additional loan tranches that was recognized as FCA. The Company has concluded that the warrants should be classified as equity since the warrants are not an ASC 480 liability, are indexed to the Company’s own Ordinary share and meet all the equity classification conditions pursuant to ASC 815-40. The Company has also concluded that the FCA is not indexed to the Company’s own Ordinary share and should be measured at fair value, with changes in fair value recognized in earnings. In addition, the First Tranche and the Second Tranche term loan were accounted for using the effective interest method. The Company allocated the proceeds received to the FCA at fair value. The remaining proceeds were allocated between the warrants and the First Tranche term loan using the relative fair value method. The proceeds allocation resulted in $9,532 allocated to the First Tranche and $468 allocated to the warrants, net of issuance costs. The proceeds allocated to the FCA were immaterial. The Company allocated the proceeds received under the Credit Line between the warrants and the Second Tranche term loan using the relative fair value method. The proceeds allocation resulted in $2,380 allocated to the Second Tranche and $120 allocated to the warrants. On March 29, 2023, the Company entered into an amendment to the Credit Line (the “Amendment”). Pursuant to the Amendment, 70% of the remaining principal and interest repayments will be delayed and repaid on a monthly equal basis from August 2024 to May 2026. The amended secured Credit Line bore interest at the rate of 10%. In addition, the Company paid to Kreos a restructuring fee consisting of 1% on the closing date of the Amendment and will pay an incremental 3% at the maturity of the Amendment. In return for this additional deferral of repayment, Kreos has the right to receive a potential claw-back payment on account of the then outstanding principal amount (the “Claw-Back”). This Claw-Back mechanism will be triggered by additional incoming funds from future collaboration and partnership agreements or additional funding. If triggered, the minimum Claw-Back to be paid will be $1,500, but will not exceed $3,000. During the first quarter of 2024, the Company repaid $1,500 due to the Claw-Back. Further to the above, the warrants to purchase 6,491 Ordinary shares of the Company issued to Kreos were repriced and as a result bear an exercise price of $12.60 per share. As a result of the modification, the Company recorded an incremental value in the amount of $31, that was calculated based on the Black-Scholes option pricing model, which increased the additional paid-in capital against an offset of the long-term debt due to the Credit Line. On August 1, 2024, the Company entered into a second amendment (the “Second Amendment”) to the Credit Line. Pursuant to the Second Amendment, 60% of the remaining principal and interest repayments under the Credit Line will be delayed and repaid on a monthly equal basis from April 1, 2025. The amended secured Credit Line now bears interest at a rate of 12.00%, and the Company will pay a restructuring fee to Kreos of $125. In return for this additional deferral of repayment, Kreos has the right to receive a potential Claw Back. The Claw Back to be paid will not exceed $4,500, out of which $1,904 was already paid as of December 31, 2024. As part of the Second Amendment, the Company issued to Kreos a warrant to purchase 40,000 Ordinary shares of the Company at an exercise price of $3.61 per share. The Company evaluated the amendments under ASC 470-50, “ Debt - modification and extinguishment The Credit Line is denominated in U.S. dollars and bears interest at an annual rate equal to 9.25% until the First Amendment, 10% from the First Amendment to the Second Amendment, and 12% From the Second Amendment. The interest paid due to the Credit Line for the years ended December 31, 2024 and 2023 amounted to $950 and $1,038, respectively. During the years ended December 31, 2024 and 2023, the Company recognized $1,651 and $1,685 of interest expenses related to the Credit Line, respectively, which were included as part of financial expenses in the Company’s statements of operations. In addition, the Company’s debt includes the Claw-Back feature, which meets the definition of embedded derivative under ASC 815 And was not clearly and closely related to the debt host. Consequently, the embedded derivative was bifurcated and accounted for separately at fair value. The fair value of the derivative amounted to $19 and $60 as of December 31, 2024 and December 31, 2023, respectively. Changes in the fair value of the derivative liabilities are determined at each period end. The liability due to the derivative was classified under other long-term liabilities in the consolidated balance sheet as of December 31, 2024. The Company incurred debt restructuring costs, which were fully paid in cash, and are presented as a direct deduction against the carrying amount of the debt and amortized to interest expense using the effective interest method.

Commitments and Contingent Liab

Commitments and Contingent Liabilities	12 Months Ended
	Dec. 31, 2024
Commitments and Contingent Liabilities [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 8:- COMMITMENTS AND CONTINGENT LIABILITIES In connection with its research and development programs, through December 31, 2024, the Company received participation payments from the IIA in the aggregate amount of $4,888. In return for the IIA’s participation, the Company is committed to pay royalties at a rate of 3% of sales of the developed products, up to 100% of the amount of grants received plus interest at SOFR rate. Through December 31, 2024, no royalties have been paid or accrued.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2024
Income Taxes [Abstract]
INCOME TAXES	NOTE 9:- INCOME TAXES a. Corporate tax rates: The corporate tax rate in Israel in 2024, 2023 and 2022 was 23%. The United States of America federal rate was 21% and the state corporate income tax rates range from 6.5% to 11.5% for the years ended December 31, 2024, 2023 and 2022. The Company is subject to United States of America income tax laws. There are no provisions for United States of America federal, state or other taxes for any period. Loss before taxes is comprised as follows : Year Ended December 31, 2024 2023 2022 Domestic (Israel) $ 28,567 $ 23,348 $ 38,274 Foreign 413 448 1,154 $ 28,980 $ 23,796 $ 39,428 b. Net operating losses carryforward: The Company has accumulated losses for tax purposes as of December 31, 2024, in the amount of approximately $198,927 which may be carried forward and offset against taxable income in the future for an indefinite period. c. Tax assessment: The Company has net operating losses from prior tax periods which may be subjected to examination in future periods. As of December 31, 2024, the Company’s tax years until December 31, 2019, are subject to the statute of limitation in Israel. The US Subsidiary has yet to receive final tax assessments since its incorporation. d. Deferred taxes: Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s deferred tax assets are comprised of operating loss carryforwards and other temporary differences. Significant components of the Company’s deferred tax assets are as follows: December 31, 2024 2023 Deferred tax assets: Carryforward losses $ 45,753 $ 40,133 Research and development expenses 4,249 4,044 Operating lease liabilities 505 292 Reserves and allowances 187 207 Deferred tax assets before valuation allowance 50,694 44,676 Valuation allowance (50,166 ) (44,338 ) Total deferred tax assets 528 338 Deferred tax liabilities: Operating lease ROU assets (528 ) (338 ) Total deferred tax liabilities (528 ) (338 ) Net deferred tax assets, net $ - $ - Management currently believes that since the Company has a history of losses, and there is uncertainty with respect to future taxable income of the Company, it is more likely than not that the deferred tax assets will not be utilized in the foreseeable future. Thus, a full valuation allowance was provided to reduce deferred tax assets to their realizable value. For 2024 and 2023, the main reconciling items of the Company’s statutory tax rate of 23% and the effective tax rate of (0.1)% and (0.3)%, respectively, were tax carryforward losses and other temporary differences, such as research and development expenses, for which a full valuation allowance was provided. e. Income taxes are comprised of current tax expenses, all foreign, which amounted to $42 and $69 for the years ended December 31, 2024 and 2023, respectively.

Shareholders_ Equity (Deficit)

Shareholders’ Equity (Deficit)	12 Months Ended
	Dec. 31, 2024
Shareholders’ Equity (Deficit) [Abstract]
SHAREHOLDERS’ EQUITY (DEFICIT)	NOTE 10:- SHAREHOLDERS’ EQUITY (DEFICIT) a. Reverse Share Split: On September 18, 2023, the Company’s board of directors approved a 1-for-30 reverse share split (See Note 1.b). Following the reverse share split, all Ordinary shares, options, warrants, exercise prices and per share data have been adjusted retroactively for all periods presented in these consolidated financial statements. b. Ordinary share capital (with no par value each) following the reverse share split is composed as follows: December 31, 2024 December 31, 2023 Authorized Issued and Authorized Issued and Number of shares Ordinary shares 107,800,000 10,190,904 107,800,000 1,653,559 c. Controlled Equity Offering Sales Agreement (the “Sales Agreement”): In November 2024, the Company entered into a Sales Agreement, with Oppenheimer & Co. Inc. (the “Agent”). Pursuant to the Sales Agreement, the Company may offer and sell, from time to time, its Ordinary shares, through the Agent in an at the market offering (“ATM’”), as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, for an aggregate offering price of up to $8,250. During the year ended December 31, 2024, the Company sold 464 Ordinary shares under the ATM for a total amount of $2, net of issuance cost. During the year ended December 31, 2023, the Company sold 75,693 Ordinary shares under a prior ATM for a total amount of $2,328, net of issuance cost in the amount of $92. d. Private placements and public offerings: On March 29, 2023, the Company entered into a private placement of unregistered pre-funded warrants to purchase up to 345,238 Ordinary shares (the “PFW”), at a price of $12.60 per PFW with certain of the Company’s existing shareholders. The PFWs have an exercise price of $0.003 per Ordinary share. Accordingly, the consideration for the PFWs amounted to $3,987, net of related placement fees and other offering expenses which amounted to a total of $362. In accordance with ASC No. 480, “ Distinguishing Liabilities from Equity Derivatives and Hedging On March 31, 2023, the Company closed a public offering which was comprised of 561,967 Ordinary shares (inclusive of 73,300 Ordinary shares pursuant to the full exercise of an overallotment option granted to the underwriters), at a public offering price of $12.60 per share (the “Public Offering”). The proceeds to the Company from the Public Offering were $6,415, net of underwriting commissions and other offering expenses which amounted to $665. Following the Public Offering, the Company did not have a sufficient number of authorized Ordinary shares to cover 167,115 PFWs, and as a result, in accordance with ASC 815-40, these PFWs, which amounted to $2,106, were classified as a liability at fair value. On May 5, 2023, the shareholders of the Company approved to increase the Company’s authorized share capital by 60,000,000, from 47,800,000 to 107,800,000 Ordinary shares, and as a result, in accordance with ASC 480 and 815-40, these PFWs were classified under equity accounting at their fair value, which amounted to $1,905. The change in the PFWs’ fair value was accounted for as financial expenses in the amount of $201. On May 11, 2023, all of the PFWs were exercised into 345,151 Ordinary shares on a cashless basis. On January 4, 2024, the Company entered into a definitive securities purchase agreement for a private placement financing, led by leading U.S. life sciences-focused investors and certain existing investors. Under the securities purchase agreement, the investors purchased 3,143,693 of the Company’s Ordinary shares at a purchase price of $4.81 per share, pre-funded warrants to purchase up to 227,619 Ordinary shares at an exercise price of $0.0001 per share and warrants to purchase up to 3,371,312 Ordinary shares at an exercise price of $5.50 per share. The warrants expire upon the earlier of two years from the date of issuance and 10 trading days following the Company’s announcement of the positive recommendation by Data Safety Monitoring Board regarding the Company’s unblinded interim analysis in its SHIELD II Phase 3 trial of D-PLEX 100 On August 1, 2024, the Company entered into a definitive securities purchase agreement for a private placement financing. Under the securities purchase agreement, the investors purchased 2,006,226 of the Company’s Ordinary shares at a purchase price of $3.61 per share, pre-funded warrants to purchase up to 229,231 Ordinary shares at an exercise price of $0.0001 per share and warrants to purchase up to 1,676,588 Ordinary shares at an exercise price of $3.61 per share. The warrants expire upon the earlier of two years from the date of issuance and 10 trading days following the Company’s announcement of the recommendation by the DSMB regarding the Company’s unblinded interim analysis in its SHIELD II Phase 3 trial of D- PLEX 100 On December 26, 2024, the Company entered into a definitive securities purchase agreement for a private placement financing. Under the securities purchase agreement, the investors purchased 3,386,962 of the Company’s Ordinary shares, at a purchase price of $3.22 per share, pre-funded warrants to purchase up to 1,106,868 Ordinary shares at an exercise price of $0.0001 per share and warrants to purchase up to 6,740,745 Ordinary shares at an exercise price of $4.00 per share. The warrants expire upon the earlier of nine months from the date of issuance and 10 trading days following the Company’s announcement of the top-line results in the Company’s SHIELD II Phase 3 trial of D-PLEX 100 e. Ordinary shares rights: The Ordinary shares confer upon their holders the right to participate in the general meetings of the Company, to vote at such meetings (each share represents one vote), and to participate in any distribution of dividends or any other distribution of the Company’s property, including the distribution of surplus assets upon liquidation. f. Share option plan: The Company has authorized through its 2012 Share Option Plan, the grant of options to officers, directors, advisors, management and other key employees of up to 2,312,403 Ordinary shares. The options granted generally have a four-year vesting period and expire ten years after the date of grant. Options granted under the Company’s option plan that are canceled or forfeited before expiration become available for future grant. On May 6, 2024, the Company’s board of directors approved to increase the Company’s options pool by an additional 2,000,000 options from 312,403 to 2,312,403. As of December 31, 2024, 492,278 of the Company’s options were available for future grants. During the first quarter of 2023, the Company decreased the exercise price of 67,385 options granted to all employees and a consultant under the 2012 Share Option Plan. As of the modification date, the options can be exercised for $23.07 (the “Repricing”). Following the Repricing, the Company accounted for an incremental value in the total amount of $562, of which $307 was recognized as of the modification date due to vested options, and the rest of the amount will be expensed based on the vesting conditions of each grant. On May 5, 2023, the Company’s board of directors also approved a similar exercise price decrease of 17,417 options previously granted to the Company’s Chief Executive Officer and board members. Therefore, the Company accounted for an incremental value in the total amount of $63, out of which $50 was recognized as of the modification date due to vested options, and the rest of the amount will be expensed based on the vesting conditions of each grant. A summary of the status of options to employees and non-employees under the Company’s option plan as of December 31, 2024, and changes during the relevant period ended on that date is presented below: Number of options Weighted average exercise price Aggregate intrinsic value Weighted contractual Outstanding at beginning of year 254,437 $ 22.41 $ - 8.24 Granted 1,623,474 4.59 Forfeited (54,952 ) 8.71 Expired (8,408 ) 74.00 Outstanding at end of year 1,814,551 $ 6.65 $ - 9.14 Exercisable options 267,776 $ 15.19 $ - 8.03 Vested and expected to vest 1,401,951 $ 7.24 $ - 9.14 The weighted average grant date fair value of options granted during the year ended December 31, 2024, was $3.80. The Black-Scholes assumptions used to value the employee and non-employee share options at the grant dates are presented in the following table by years: 2024 2023 2022 Dividend yield (%) 0 0 0 Expected volatility (%) 97.1-103.0 92.59-95.67 70.45-93.85 Risk-free interest rate (%) 3.74-5.06 3.38-4.71 1.81-4.31 Expected term (in years) 0.5-6.1 5.3-6.1 1.2-6.2 These assumptions and estimates were determined as follows: o Fair Value of Ordinary Shares - The fair value of each Ordinary share was based on the closing price of the Company’s publicly traded Ordinary shares as reported on the date of the grant. o Dividend Yield - The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. As a result, an expected dividend yield of zero percent was used. o Expected Volatility - As the Company has a short trading history for its Ordinary shares, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company’s industry that the Company considers to be comparable to its own business over a period equivalent to the option’s expected term. o Risk-Free Interest Rate - The risk-free rate for the expected term of the options is based on the Black-Scholes option pricing model on the yields of United States of America Treasury securities with maturities appropriate for the expected term of employee share option awards. o Expected term - The expected term represents the period that options are expected to be outstanding. For option grants that are considered to be “plain vanilla,” the Company determines the expected term using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the options. The total share-based compensation expense recognized by the Company’s departments for the three years ended December 31, 2024, 2023 and 2022, was comprised as follows: Year Ended December 31, 2024 2023 2022 Research and development $ 1,539 $ 1,791 $ 2,081 Marketing and business development 291 339 383 General and administrative 994 1,261 1,843 Total $ 2,824 $ 3,391 $ 4,307 As of December 31, 2024, there were unrecognized compensation costs of $5,599, which are expected to be recognized over a weighted average period of approximately 2.74 years. On May 6, 2024, the Board of directors granted a total of 280,000 milestone-based options to the Company’s officers and on July 2, 2024, the Company’s shareholders approved a grant of 132,600 milestone-based options to the Company’s Chief Executive Officer (collectively, the “Milestone-Based Options”). The milestone condition was set as either the interim analysis outcome of early stopping of the Company’s SHIELD II Phase 3 trial of D-PLEX 100 The average exercise price for Milestone-Based Options is $4.64 per share. As of December 31, 2024, the milestone condition is not probable of being achieved; therefore, no compensation costs were recognized. g. Warrants and pre-funded warrants: Further to the discussion in Note 7, as of April 26, 2022, July 19, 2022 and August 1, 2024, the Company measured the fair value of the warrants to purchase Ordinary shares (a Level 3 valuation) using the Black-Scholes option pricing model. As of April 26, 2022, July 19, 2022 and August 1, 2024, the relative fair value of the warrants to purchase Ordinary shares issued to Kreos was $468, $120 and $115, respectively, which was calculated using the following assumptions: July 19, April 26, August 1, 2022 2022 2024 Share price ($) 153.60 148.80 3.65 Exercise price ($) 154.05 154.05 3.61 Expected volatility (%) 60.57 60.81 88 Adjustment to risk-free interest rate (%) 3.07 2.84 3.89 Dividend yield (%) - - - Risk-free interest rate (%) 3.11 2.88 3.89 Expected life (in years) 6.72 6.94 7.00 Further to the discussion in Note 10d, as of January 9, 2024, August 6, 2024 and December 26, 2024, the Company measured the fair value of the warrants to purchase Ordinary shares (a Level 3 valuation) using the Black-Scholes option pricing model. As of January 9, 2024, August 6, 2024 and December 26, 2024, the relative fair value of the warrants to purchase Ordinary shares issued was $15,248, $1,733 and $2,101, respectively, which was calculated using the following assumptions: January 9, August 6, December 26, 2024 2024 2024 Share price ($) 6.89 3.50 2.85 Exercise price ($) 5.50 3.61 4.00 Expected volatility (%) 117.4-134 95-129 77.48 Adjustment to risk-free interest rate (%) 4.27-5.96 3.91-4.98 4.22 Dividend yield (%) - - - Risk-free interest rate (%) 4.36-5.08 3.99-5.11 4.31 Expected life (in years) 0.68-2.00 0.40-2.00 0.5 As of December 31, 2024, all warrants are exercisable into Ordinary shares, in which the outstanding issued warrants to purchase Ordinary shares as of December 31, 2024, were as follows: Grant date Warrants as of December 31, Average price per share ($) Warrants as of December 31, Exercisable April 2022 5,193 $ 12.60 5,193 April 2029 July 2022 1,298 $ 12.60 1,298 April 2029 January 2024 3,371,312 $ 5.50 3,371,312 January 2026 *) January 2024 227,619 $ 0.0001 227,619 No maturity date *) August 2024 1,676,588 $ 3.61 1,676,588 August 2026 *) August 2024 229,231 $ 0.0001 229,231 No maturity date *) August 2024 40,000 $ 3.61 40,000 August 2031 December 2024 6,740,745 $ 4.00 6,740,745 September 2025 *) December 2024 1,106,868 $ 0.0001 1,106,868 No maturity date *) 13,398,854 13,398,854 No warrants were exercised during the year ended December 31, 2024. *) See Note 10d.

Financial Expenses, Net

Financial Expenses, Net	12 Months Ended
	Dec. 31, 2024
Financial Expenses, Net [Abstract]
FINANCIAL EXPENSES, NET	NOTE 11:- FINANCIAL EXPENSES, NET Year Ended December 31, 2024 2023 2022 Financial expenses: Financial expenses from credit line and derivative $ 1,510 $ 1,618 $ 1,023 Other financial expenses 15 93 316 Total 1,525 1,711 1,339 Financial income: Foreign currency transaction gains, net (113 ) (33 ) (532 ) Interest income from bank deposits (442 ) (548 ) (267 ) Other financial income (19 ) - - Remeasurement of warrants - (201 ) - Total (574 ) (782 ) (799 ) Total $ 951 $ 929 $ 540

Basic and Diluted Net Loss Per

Basic and Diluted Net Loss Per Share	12 Months Ended
	Dec. 31, 2024
Basic and Diluted Net Loss Per Share [Abstract]
BASIC AND DILUTED NET LOSS PER SHARE	NOTE 12:- BASIC AND DILUTED NET LOSS PER SHARE Basic loss per share is computed using the weighted-average number of outstanding Ordinary shares during the period. Diluted loss per share is computed using the weighted-average number of outstanding Ordinary shares and, when dilutive, potential Ordinary shares outstanding during the period. The computation of loss per share is as follows: Year Ended December 31, 2024 2023 2022 Basic loss per share: Net loss $ 29,022 $ 23,865 $ 39,557 Shares used in computation: Weighted-average shares of Ordinary shares outstanding 5,912,890 1,404,368 647,556 Basic loss per share $ 4.91 $ 16.99 $ 61.09 Diluted loss per share: Net loss $ 29,022 $ 24,066 $ 39,557 Shares used in computation: Weighted-average shares of Ordinary shares outstanding 5,912,890 1,421,308 647,556 Diluted loss per share $ 4.91 $ 16.93 $ 61.09 The potential ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have been anti-dilutive are as follows: December 31, 2024 2023 2022 Number of Ordinary shares Ordinary share options 267,776 71,456 82,914 Warrants 13,398,854 7,088 13,775 13,666,630 78,544 96,689

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 13:- SUBSEQUENT EVENTS On January 6, 2025, the Company entered into a third amendment (the “Third Amendment”) to the Credit Line. Pursuant to the Third Amendment, 60% of the principal and interest repayments which are originally scheduled to be paid until the end of June 2025, will now be delayed and repaid in July 2025. The Company will pay a restructuring fee to Kreos of $160 in July 2025 and the end of loan payment shall be increased from 5% to 7%.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ (29,022)	$ (23,865)	$ (39,557)

Insider Trading Policies and Pr

Insider Trading Policies and Procedures	3 Months Ended
	Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Cybersecurity Risk Management a

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
	Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	Our Board recognizes the critical importance of maintaining the trust and confidence of our business partners and employees. The Board is actively involved in oversight of our risk management program, and cybersecurity represents an important component of our overall approach to risk management. Our cybersecurity policies, standards, processes and practices are fully integrated into our risk management program and are based on recognized frameworks established by HIPAA, GDPR and GMP industry standards. In general, we seek to address cybersecurity risks through a comprehensive, cross-functional approach that is focused on preserving the confidentiality, security and availability of the information that we collect and store by identifying, preventing and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur. Risk Management and Strategy As part of the critical elements of our overall risk management approach, our cybersecurity program is focused on the following key areas: ● Governance: As discussed in more detail under the heading “Governance,” the Board oversees our risk management process, including the management of risks arising from cybersecurity threats. ● Collaborative Approach: The Company has implemented a comprehensive, cross-functional approach to identifying, preventing and mitigating cybersecurity threats and incidents, while also implementing controls and procedures that provide for the prompt escalation of certain cybersecurity incidents so that decisions regarding the public disclosure and reporting of such incidents can be made by management in a timely manner. ● Technical Safeguards: The Company deploys technical safeguards that are designed to protect the Company’s information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence. ● Incident Response and Recovery Planning: The Company has established and maintains comprehensive incident response and recovery plans that fully address the Company’s response to a cybersecurity incident, and such plans are tested and evaluated on a regular basis. ● Education and Awareness: The Company provides regular, mandatory training for personnel regarding cybersecurity threats as a means to equip the Company’s personnel with effective tools to address cybersecurity threats, and to communicate the Company’s evolving information security policies, standards, processes and practices. We engage in the periodic assessment and testing of our policies, standards, processes and practices that are designed to address cybersecurity threats and incidents. These efforts include a wide range of activities, including audits, assessments, threat modeling, vulnerability testing, and other exercises focused on evaluating the effectiveness of our cybersecurity measures and planning. We periodically engage third parties to perform assessments on our cybersecurity measures, including information security maturity assessments, audits and independent reviews of our information security control environment and operating effectiveness. The results of such assessments, audits and reviews are reported to the Audit Committee and the Board, and we adjust our cybersecurity policies, standards, processes and practices as necessary based on the information provided by these assessments, audits and reviews.
Cybersecurity Risk Management Processes Integrated [Text Block]	Our cybersecurity policies, standards, processes and practices are fully integrated into our risk management program and are based on recognized frameworks established by HIPAA, GDPR and GMP industry standards.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Board of Directors Oversight [Text Block]	Governance The Board oversees our risk management process, including the management of risks arising from cybersecurity threats. The Board receives periodic presentations and reports on cybersecurity risks, which address a wide range of topics including recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, technological trends and information security considerations arising with respect to our third parties. The Board also receives prompt and timely information regarding any cybersecurity incident that meets established reporting thresholds, as well as ongoing updates regarding any such incident until it has been addressed. The Company’s IT Manager works collaboratively across the Company to implement a program designed to protect the Company’s information systems from cybersecurity threats and to promptly respond to any cybersecurity incidents in accordance with the Company’s incident response and recovery plans. To facilitate the success of the Company’s cybersecurity risk management program, external third party vendors are retained to address cybersecurity threats and to respond to cybersecurity incidents. The IT Manager monitors the prevention, detection, mitigation and remediation of cybersecurity threats and incidents in real time, and will report such threats to Company’s management and Board. Our former IT Manager left our company on December 10, 2024. While we are currently recruiting a new candidate for the position of IT Manager, we are utilizing the services of an external IT firm YouCC Technologies Ltd. in the interim. Cybersecurity threats, including as a result of any previous cybersecurity incidents, have not materially affected or are reasonably likely to affect the Company, including its business strategy, results of operations or financial condition.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Board receives periodic presentations and reports on cybersecurity risks, which address a wide range of topics including recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, technological trends and information security considerations arising with respect to our third parties. The Board also receives prompt and timely information regarding any cybersecurity incident that meets established reporting thresholds, as well as ongoing updates regarding any such incident until it has been addressed.
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	The IT Manager monitors the prevention, detection, mitigation and remediation of cybersecurity threats and incidents in real time, and will report such threats to Company’s management and Board.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Role of Management [Text Block]	The Company’s IT Manager works collaboratively across the Company to implement a program designed to protect the Company’s information systems from cybersecurity threats and to promptly respond to any cybersecurity incidents in accordance with the Company’s incident response and recovery plans. To facilitate the success of the Company’s cybersecurity risk management program, external third party vendors are retained to address cybersecurity threats and to respond to cybersecurity incidents. The IT Manager monitors the prevention, detection, mitigation and remediation of cybersecurity threats and incidents in real time, and will report such threats to Company’s management and Board.
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]	Cybersecurity threats, including as a result of any previous cybersecurity incidents, have not materially affected or are reasonably likely to affect the Company, including its business strategy, results of operations or financial condition.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2024
Significant Accounting Policies [Abstract]
Use of estimates	a. Use of estimates: The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.
Consolidated financial statements in U.S. dollars	b. Consolidated financial statements in U.S. dollars: The accompanying consolidated financial statements have been prepared in United States of America dollars (“$” or “U.S. dollars”). A substantial portion of the Company’s expenses are incurred in New Israeli Shekels (“NIS”). However, the Company finances its operations mainly in U.S. dollars, a substantial portion of its expenses are incurred in U.S. dollars and potential revenues from its primary markets are anticipated to be generated in U.S. dollars. As such, the Company’s management believes that the U.S. dollar is the currency of the primary economic environment in which the Company and its subsidiaries operate. Thus, the functional and reporting currency of the Company is the U.S. dollar. Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the dollar are re-measured into U.S. dollars in accordance with Accounting Standards Codification (“ASC”) No. 830, “ Foreign Currency Matters
Principles of consolidation	c. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances have been eliminated upon consolidation.
Cash equivalents	d. Cash equivalents: Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three months or less, at the date acquired.
Restricted deposits	e. Restricted deposits: Restricted cash is primarily invested in a bank deposit and is used as security for the Company’s lease commitments and for its forward and options transactions activities (see Note 2p).
Segment reporting	f. Segment reporting: The Company identifies operating segments in accordance with ASC No. 280, “Segment Reporting”, as components of an entity for which discrete financial information is available and is regularly reviewed by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and evaluating financial performance. The Company’s chief operating decision maker (“CODM”) is its chief executive officer, who manages the Company’s business activities as a single operating and reportable segment on a consolidated basis. Accordingly, the CODM uses consolidated net loss to assess financial performance and allocate resources. The CODM reviews and utilizes functional expenses (research and development, sales and marketing, and general and administrative) at the consolidated level as presented in the Company’s consolidated statements of operations, to manage the Company’s operations. Other financial information regarding the Company’s operating segment is presented elsewhere in consolidated financial statements.
Short-term deposits	g. Short-term deposits: A short-term bank deposit is a deposit with a maturity of more than three months, but less than one year. Short-term deposits are presented at cost, which approximates market value due to their short maturities.
Property and equipment, net	h. Property and equipment, net: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers and software 33 Laboratory equipment 10 - 15 Furniture and office equipment 15 Leasehold improvements Over the shorter of the term of the lease or its useful life
Leases	i. Leases: The Company adopted ASC No. 842, “ Leases Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably certain to be exercised, the lease term is for a major part of the remaining useful life of the asset, the present value of the lease payments equals or exceeds substantially all of the fair value of the asset, or the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if it does not meet any one of these criteria. Since all of the Company’s lease contracts do not meet any of the criteria above, the Company concluded that all of its lease contracts should be classified as operating leases. Right-of-use (“ROU”) assets and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on information available on the commencement date in determining the present value of lease payments. All ROU assets are reviewed for impairment. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. The Company also elected the practical expedient to not separate lease and non-lease components for its leases. The Company elected to not recognize a lease liability and a ROU asset for lease with a term of twelve
Impairment of long-lived assets	j. Impairment of long-lived assets: The Company’s long-lived assets are reviewed for impairment in accordance with ASC No. 360, “ Property, Plant and Equipment As of December 31, 2024 and 2023, no impairment losses have been identified.
Research and development, net expenses	k. Research and development, net expenses: Research and development expenses consist of personnel costs (including salaries, benefits and share-based compensation), materials, consulting fees and payments to subcontractors, chemical, manufacturing and control activities, costs associated with obtaining regulatory approvals, executing pre-clinical and clinical studies and maintenance and prosecution of the Company’s intellectual property rights. In addition, research and development expenses include overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development expenses as expenses when incurred and are presented net of government grants (see Note 2l).
Grants and participations	l. Grants and participations: Royalty-bearing grants from the Israeli Innovation Authority (“IIA”) of the Ministry of Economy and Industry in Israel for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and development expenses. Non-royalty-bearing grants from the IIA MAGNET program and from European Commission’s Seventh Framework Programme for Research (“FP7”) for funding approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and development expenses. Since the payment of royalties is not probable when the grants are received, the Company does not record a liability for amounts received from IIA until the related revenues are recognized. In the event of failure of a project that was partly financed by IIA, the Company will not be obligated to pay any royalties or repay the amounts received. The Company recognizes participations in research and development, as a reduction from research and development expenses in the amount of $0, $83 and $738 for the years ended December 31, 2024, 2023, and 2022, respectively. From inception up until December 31, 2024, the Company received a total of $7,290 in grants, out of which royalty-bearing grants in the amount of $4,888 from the IIA, non-royalty bearing grants in the amount of $1,675 from the IIA and non-royalty bearing grants in the amount of $727 from the FP7.
Accounting for share-based compensation	m. Accounting for share-based compensation: Share-based compensation expense related to share-based awards is recognized based on the fair value of the awards granted and recognized as an expense on a straight-line basis over the requisite service period for share options. The fair value of each option award is estimated on the grant date using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including the expected term of the award, the expected volatility of the price of the Company’s Ordinary shares, risk-free interest rates, and the expected dividend yield of Ordinary shares. The assumptions used to determine the fair value of the share awards represent management’s best estimates. These estimates involve inherent uncertainties and the application of management’s judgment. Forfeitures are accounted for as they occur instead of estimating the number of awards expected to be forfeited.
Basic and diluted net loss per share	n. Basic and diluted net loss per share: The Company’s basic net loss per share is calculated by dividing the net loss attributable to Ordinary shareholders by the weighted-average number of shares of Ordinary shares outstanding for the period, without consideration of potentially dilutive securities. The diluted net loss per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method or the if-converted method based on the nature of such securities. Diluted net loss per share is the same as basic net loss per share in periods when the effects of potentially dilutive shares of Ordinary shares are anti-dilutive.
Fair value of financial instruments	o. Fair value of financial instruments: The Company applies ASC No. 820, “ Fair Value Measurements and Disclosures Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. Fair value is an exit price, representing the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value: Level 1 - Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities. Level 2 - Include other inputs that are directly or indirectly observable in the marketplace. Level 3 - Unobservable inputs which are supported by little or no market activity The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value . The carrying amounts of cash and cash equivalents, restricted deposits, prepaid expenses and other current assets, other long term assets, trade payables, accrued expenses and other current and non-current liabilities approximate their fair value due to the short-term maturity of such instruments. The fair value measurement of the Financial Component Asset (“FCA”) is measured using unobservable inputs that require a high level of judgment to determine fair value, and thus is classified as a Level 3 financial instrument. The Company estimates the fair value of the abovementioned instrument using the Monte-Carlo simulation and the Black-Scholes option pricing model. Fair value estimates are made at a specific point in time, based on relevant market information and information about the financial instruments. These estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect these estimates.
Derivative financial instruments	p. Derivative financial instruments: The Company accounts for derivatives based on ASC 815. ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. The Company enters into option and forward contracts in order to limit the exposure to exchange rate fluctuation associated with expenses mainly incurred in NIS. Since the derivative instruments that the Company holds were not designated as hedging instruments under ASC 815, any gain or loss derived from such instruments is recognized immediately as “financial expense, net”. The Company measured the fair value of the contracts in accordance with ASC 820. Foreign currency derivative contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. As of December 31, 2024 and 2023, the fair value of the options and forward contracts was $0. Financial expense (income) for the years ended December 31, 2024, 2023 and 2022, amounted to $(19), $75 and 273, respectively.
Income taxes	q. Income taxes: The Company accounts for income taxes in accordance with ASC No. 740, “ Income Taxes ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2024 and 2023, the Company’s uncertain tax position liability was $208 and $170, respectively. The Company’s policy is to accrue interest and penalties related to unrecognized tax benefits in its taxes on income.
Revenue recognition	r. Revenue recognition: The Company recognizes revenue from contracts with customers under ASC No. 606, “ Revenue from Contracts with Customers To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assesses whether each good or service is distinct to determine the performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. On August 2, 2022, the Company entered into a license, distribution and supply agreement (the “Agreement”) with Mercury Pharma Group Limited, under the trade name Advanz Pharma Holdings (the “Customer”), with respect to the Company’s product, the D-PLEX 100 The term of the Agreement is until the later of December 31, 2035, or 10 years after the first commercial sale of the Product. The Agreement can also be terminated by either party under certain limited circumstances. Pursuant to the Agreement, the Customer was granted an exclusive license to market, commercialize, and distribute the Product in the European Economic Area and in the United Kingdom. Under the Agreement, the Company will carry out all activities required to obtain marketing authorization in each territory, approving the commercial sale of the Product in that territory. Once marketing authorization will be granted in a territory, the Customer will be required to achieve minimum sales requirements for that territory. Under the terms of the Agreement, the Company received a non-refundable, one-time payment of €2.5 million (approximately $2,548). The Company is also entitled to receive additional development-related milestones payments for a total of up to €23 million. In addition, the Company will be entitled to receive up to additional €87 million upon achievement of certain commercial sale milestones. The Company has concluded that the Agreement includes a single performance obligation. The Company has concluded that the license and development are not distinct from the manufacturing since the Customer could not use, consume, or sell the license and development services on their own or with resources readily available to the Customer because of the Company’s specialized knowledge and the associated manufacturing know-how and because currently, and in the foreseeable future, there are no other parties that could manufacture the Product. As such, the transaction price was fully allocated to the single performance obligation. Since it is not probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the milestone payments is resolved, the Company estimated the transaction price at €2.5 million (approximately $2,548). As of December 31, 2024, the Company has yet to satisfy its performance obligation under the Agreement and, therefore, no revenues were recognized. Accordingly, the upfront payment amount was classified as a long-term deferred revenue in the Company’s consolidated balance sheet as of December 31, 2024.
Concentration of credit risks	s. Concentration of credit risks: Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and restricted deposits. Cash, cash equivalents and restricted deposits are deposited in major banks in Israel and in the United States of America. Such investments may be in excess of insured limits or not insured. Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal risk. The Company utilizes option and forward contracts to protect against the risk of overall changes in exchange rates. The derivative instruments hedge a portion of the Company’s non-dollar currency exposure. Counterparties to the Company’s derivative instruments are all major financial institutions.
Severance pay	t. Severance pay: All the Company’s employees who are Israeli citizens have subscribed to Section 14 of Israel’s Severance Pay Law, 5723-1963 (“Section 14”). Pursuant to Section 14, employees covered by this section are entitled to monthly deposits at a rate of 8.33% of their monthly salary, made on their behalf by the Company. Payments in accordance with Section 14 release the Company from any future severance liabilities in respect of those employees. Neither severance pay liability nor severance pay fund under Section 14 for such employees is recorded on the Company’s consolidated balance sheets. Severance pay expense for the years ended December 31, 2024, 2023 and 2022, amounted to $404, $401 and $537, respectively. The US Subsidiary has a Safe Harbor 401(k) plan covering all the US Subsidiary employees. All eligible employees may elect to contribute up to 100% of their payroll compensation (minus mandatory payroll deductions) to the plan, for 2024, up to a maximum of $23 per year (for employees over 50 years of age the maximum contribution was $31 per year), as determined by the U.S. Internal Revenue Service (“IRS”). The US Subsidiary matches at 100%, on each payroll, up to 5% of the employee compensation to the plan within the IRS limits (which was set at $345 in 2024 for purposes of the plan).
Contingent liabilities	u. Contingent liabilities: The Company accounts for its contingent liabilities in accordance with ASC No. 450, “ Contingencies With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. The Company is occasionally a party to routine claims or litigation incidental to its business. The Company does not believe that it is a party to any pending legal proceeding that is likely to have a material adverse effect on its business, financial condition or results of operations. The Company recorded an accrual in the consolidated statement of operations, which it deems appropriate. As of December 31, 2024 and 2023, no liability due to legal matters has been accrued.
Recently adopted accounting pronouncements	v. Recently adopted accounting pronouncements: As an “Emerging Growth Company”, the Jumpstart Our Business Startups Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election. In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures”, which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted ASU 2023-07 during the year ended December 31, 2024.
Recently issued accounting pronouncements, not yet adopted	w. Recently issued accounting pronouncements, not yet adopted: In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company for fiscal years beginning after December 15, 2025, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09. In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses

Significant Accounting Polici_2

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2024
Significant Accounting Policies [Abstract]
Schedule of Property and Equipment Useful Life	Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers and software 33 Laboratory equipment 10 - 15 Furniture and office equipment 15 Leasehold improvements Over the shorter of the term of the lease or its useful life

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2024
Prepaid Expenses and Other Current Assets [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	December 31, 2024 2023 Prepaid expenses $ 330 $ 352 Government authorities 166 96 Other current assets 268 10 $ 764 $ 458

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2024
Property and Equipment, Net [Abstract]
Schedule of Property and Equipment, Net	December 31, 2024 2023 Cost: Computers and software $ 630 $ 620 Laboratory equipment 8,167 8,122 Furniture and office equipment 173 173 Leasehold improvements 6,524 6,503 15,494 15,418 Less - Accumulated depreciation (9,419 ) (7,797 ) Depreciated cost $ 6,075 $ 7,621

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Schedule of Lease Liability	Lease liability as of December 31, 2024, is as follows: 2025 $ 999 2026 966 2027 484 Total undiscounted lease payments 2,449 Less - imputed interest (253 ) Present value of lease liabilities $ 2,196
Schedule of Supplemental Cash Flow Information Related to the Lease Costs	The following table presents supplemental cash flow information related to the lease costs for operating leases as of December 31, 2024: Cash paid for amounts included in measurement of lease liability: Operating cash flows for operating leases $ 900 ROU asset recognized with corresponding lease liability: Operating leases $ 1,522

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2024
Accrued Expenses and Other Current Liabilities [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	December 31, 2024 2023 Accrued expenses $ 1,464 $ 995 Employees and payroll accruals 1,079 958 Other liabilities 23 18 $ 2,566 $ 1,971

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2024
Income Taxes [Abstract]
Schedule of Loss Before Taxes	Loss before taxes is comprised as follows : Year Ended December 31, 2024 2023 2022 Domestic (Israel) $ 28,567 $ 23,348 $ 38,274 Foreign 413 448 1,154 $ 28,980 $ 23,796 $ 39,428
Schedule of Deferred Tax Assets	Significant components of the Company’s deferred tax assets are as follows: December 31, 2024 2023 Deferred tax assets: Carryforward losses $ 45,753 $ 40,133 Research and development expenses 4,249 4,044 Operating lease liabilities 505 292 Reserves and allowances 187 207 Deferred tax assets before valuation allowance 50,694 44,676 Valuation allowance (50,166 ) (44,338 ) Total deferred tax assets 528 338 Deferred tax liabilities: Operating lease ROU assets (528 ) (338 ) Total deferred tax liabilities (528 ) (338 ) Net deferred tax assets, net $ - $ -

Shareholders_ Equity (Deficit)

Shareholders’ Equity (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2024
Shareholders’ Equity (Deficit) [Abstract]
Schedule of Ordinary Share Capital	Ordinary share capital (with no par value each) following the reverse share split is composed as follows: December 31, 2024 December 31, 2023 Authorized Issued and Authorized Issued and Number of shares Ordinary shares 107,800,000 10,190,904 107,800,000 1,653,559
Schedule of Status of Options to Employees	A summary of the status of options to employees and non-employees under the Company’s option plan as of December 31, 2024, and changes during the relevant period ended on that date is presented below: Number of options Weighted average exercise price Aggregate intrinsic value Weighted contractual Outstanding at beginning of year 254,437 $ 22.41 $ - 8.24 Granted 1,623,474 4.59 Forfeited (54,952 ) 8.71 Expired (8,408 ) 74.00 Outstanding at end of year 1,814,551 $ 6.65 $ - 9.14 Exercisable options 267,776 $ 15.19 $ - 8.03 Vested and expected to vest 1,401,951 $ 7.24 $ - 9.14
Schedule of Employee and Non-Employee Share Options at the Grant Dates	The Black-Scholes assumptions used to value the employee and non-employee share options at the grant dates are presented in the following table by years: 2024 2023 2022 Dividend yield (%) 0 0 0 Expected volatility (%) 97.1-103.0 92.59-95.67 70.45-93.85 Risk-free interest rate (%) 3.74-5.06 3.38-4.71 1.81-4.31 Expected term (in years) 0.5-6.1 5.3-6.1 1.2-6.2
Schedule of Share-Based Compensation Expense Recognized	The total share-based compensation expense recognized by the Company’s departments for the three years ended December 31, 2024, 2023 and 2022, was comprised as follows: Year Ended December 31, 2024 2023 2022 Research and development $ 1,539 $ 1,791 $ 2,081 Marketing and business development 291 339 383 General and administrative 994 1,261 1,843 Total $ 2,824 $ 3,391 $ 4,307
Schedule of Relative Fair Value of the Warrants to Purchase Ordinary Shares Issued	As of April 26, 2022, July 19, 2022 and August 1, 2024, the relative fair value of the warrants to purchase Ordinary shares issued to Kreos was $468, $120 and $115, respectively, which was calculated using the following assumptions: July 19, April 26, August 1, 2022 2022 2024 Share price ($) 153.60 148.80 3.65 Exercise price ($) 154.05 154.05 3.61 Expected volatility (%) 60.57 60.81 88 Adjustment to risk-free interest rate (%) 3.07 2.84 3.89 Dividend yield (%) - - - Risk-free interest rate (%) 3.11 2.88 3.89 Expected life (in years) 6.72 6.94 7.00 As of January 9, 2024, August 6, 2024 and December 26, 2024, the relative fair value of the warrants to purchase Ordinary shares issued was $15,248, $1,733 and $2,101, respectively, which was calculated using the following assumptions: January 9, August 6, December 26, 2024 2024 2024 Share price ($) 6.89 3.50 2.85 Exercise price ($) 5.50 3.61 4.00 Expected volatility (%) 117.4-134 95-129 77.48 Adjustment to risk-free interest rate (%) 4.27-5.96 3.91-4.98 4.22 Dividend yield (%) - - - Risk-free interest rate (%) 4.36-5.08 3.99-5.11 4.31 Expected life (in years) 0.68-2.00 0.40-2.00 0.5
Schedule of Warrants Exercisable Into Ordinary Shares	As of December 31, 2024, all warrants are exercisable into Ordinary shares, in which the outstanding issued warrants to purchase Ordinary shares as of December 31, 2024, were as follows: Grant date Warrants as of December 31, Average price per share ($) Warrants as of December 31, Exercisable April 2022 5,193 $ 12.60 5,193 April 2029 July 2022 1,298 $ 12.60 1,298 April 2029 January 2024 3,371,312 $ 5.50 3,371,312 January 2026 *) January 2024 227,619 $ 0.0001 227,619 No maturity date *) August 2024 1,676,588 $ 3.61 1,676,588 August 2026 *) August 2024 229,231 $ 0.0001 229,231 No maturity date *) August 2024 40,000 $ 3.61 40,000 August 2031 December 2024 6,740,745 $ 4.00 6,740,745 September 2025 *) December 2024 1,106,868 $ 0.0001 1,106,868 No maturity date *) 13,398,854 13,398,854 *) See Note 10d.

Financial Expenses, Net (Tables

Financial Expenses, Net (Tables)	12 Months Ended
	Dec. 31, 2024
Financial (Income) Expenses, Net [Abstract]
Schedule of Financial Expenses, Net	Year Ended December 31, 2024 2023 2022 Financial expenses: Financial expenses from credit line and derivative $ 1,510 $ 1,618 $ 1,023 Other financial expenses 15 93 316 Total 1,525 1,711 1,339 Financial income: Foreign currency transaction gains, net (113 ) (33 ) (532 ) Interest income from bank deposits (442 ) (548 ) (267 ) Other financial income (19 ) - - Remeasurement of warrants - (201 ) - Total (574 ) (782 ) (799 ) Total $ 951 $ 929 $ 540

Basic and Diluted Net Loss Pe_2

Basic and Diluted Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2024
Basic and Diluted Net Loss Per Share [Abstract]
Schedule of Basic and Diluted Loss Per Ordinary Share	The computation of loss per share is as follows: Year Ended December 31, 2024 2023 2022 Basic loss per share: Net loss $ 29,022 $ 23,865 $ 39,557 Shares used in computation: Weighted-average shares of Ordinary shares outstanding 5,912,890 1,404,368 647,556 Basic loss per share $ 4.91 $ 16.99 $ 61.09 Diluted loss per share: Net loss $ 29,022 $ 24,066 $ 39,557 Shares used in computation: Weighted-average shares of Ordinary shares outstanding 5,912,890 1,421,308 647,556 Diluted loss per share $ 4.91 $ 16.93 $ 61.09
Schedule of Diluted Net Loss Per Share Attributable to Ordinary Shareholders	The potential ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have been anti-dilutive are as follows: December 31, 2024 2023 2022 Number of Ordinary shares Ordinary share options 267,776 71,456 82,914 Warrants 13,398,854 7,088 13,775 13,666,630 78,544 96,689

General (Details)

General (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
General [Abstract]
Incorporation date	Feb. 28, 2008
Reverse stock split, description	On September 18, 2023, the Company’s board of directors approved 1-for-30 reverse share split
Description administration	the Company announced top-line results from the Surgical site Hospital acquired Infection prEvention with Local D-PLEX100 (“SHIELD”) I Phase 3 trial. SHIELD I did not achieve its primary endpoint of reduction in Surgical Site Infections (“SSIs”), re-interventions due to SSIs and mortality: in the Intent to Treat (“ITT”) population, the local administration of D-PLEX100 and standard of care (“SoC”), (n=485) resulted in a decrease in the primary endpoint of 23 percent compared to SoC alone (n=489) (p=0.1520).That said, in a pre-specified subgroup ITT analysis requested by the United States (“U.S.”) Food and Drug Administration (“FDA”) of a total of 423 subjects with large incisions (>20 centimeters), the local administration of D-PLEX100 resulted in a significant reduction of 54 percent in the primary endpoint, compared to SoC alone (p=0.0032). Within the first 30 days post-surgery, SSIs decreased from 9.7% in the SoC treatment arm (n=211), as compared to 4.4% in the D-PLEX100 treatment arm (n=212).In November 2022, the Company provided the FDA with available data from the SHIELD I study as part of a Type D meeting request. Following positive Type D meeting communication with the FDA, which took place in January 2023, on the SHIELD I Phase 3 data, the Company now has a clear regulatory pathway towards a potential new drug application (“NDA”) submission. Based on the data, particularly the 54% reduction observed in the primary endpoint in complex surgeries in a pre-specified subgroup analysis of patients with large open incisions (p=0.0032, n=423) compared to SoC, the FDA acknowledged that the SHIELD I results may provide supportive evidence on this population and recommended that the Company conduct an additional study to support a potential NDA submission. The FDA stated that the ongoing SHIELD II study could potentially serve as such a study. The FDA also recognized that D-PLEX100’s proposed indication is for the prevention of infection and has the potential for wide use.
Cash	$ 15,641	$ 5,309	$ 8,552
Net loss	(29,022)	(23,865)	(39,557)
Cash flows from operating activities	(21,963)	(17,236)	$ (34,317)
Accumulated deficit	$ (267,331)	$ (238,309)

Significant Accounting Polici_3

Significant Accounting Policies (Details) $ in Thousands, € in Millions	12 Months Ended
	Dec. 31, 2024 USD ($)	Dec. 31, 2024 EUR (€)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2024 EUR (€)
Significant Accounting Policies [Line Items]
Lease term	12 months				12 months
Research and development expenses	$ 0		$ 83	$ 738
Received total amount	7,290
Royalty bearing grants amount	4,888
Non-royalty bearing grants amount	1,675
Non-royalty bearing grants amount	727
Fair value	$ 0		0
Tax benefit, percentage	50%				50%
Uncertain tax liability	$ 208		170
Agreement term	10 years	10 years
Non-refundable amount	$ 2,548	€ 2.5
Additional development-related milestones payments (in Euro) | €		23
Additional amount of commercial sale milestones (in Euro) | €		€ 87
Transaction price	$ 2,548				€ 2.5
Monthly deposits percentage rate	8.33%				8.33%
Severance pay expense	$ 404		401	537
ASC 815 [Member]
Significant Accounting Policies [Line Items]
Financial expense (income)	$ (19)		$ 75	$ 273

Significant Accounting Polici_4

Significant Accounting Policies - Schedule of Property and Equipment Useful Life (Details)	Dec. 31, 2024
Computers and Software [Member]
Significant Accounting Policies - Schedule of Property and Equipment Useful Life (Details) [Line Items]
Property, Plant and Equipment, Salvage Value, Percentage	33%
Furniture and Office Equipment [Member]
Significant Accounting Policies - Schedule of Property and Equipment Useful Life (Details) [Line Items]
Property, Plant and Equipment, Salvage Value, Percentage	15%
Land Improvements [Member]
Significant Accounting Policies - Schedule of Property and Equipment Useful Life (Details) [Line Items]
Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]	Over the shorter of the term of the lease or its useful life
Minimum [Member] | Laboratory equipment [Member]
Significant Accounting Policies - Schedule of Property and Equipment Useful Life (Details) [Line Items]
Property, Plant and Equipment, Salvage Value, Percentage	10%
Maximum [Member] | Laboratory equipment [Member]
Significant Accounting Policies - Schedule of Property and Equipment Useful Life (Details) [Line Items]
Property, Plant and Equipment, Salvage Value, Percentage	15%

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - Prepaid Expenses and Other Current Assets [Member] - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Schedule of Prepaid Expenses and Other Current Assets [Line Items]
Prepaid expenses	$ 330	$ 352
Government authorities	166	96
Other current assets	268	10
Prepaid expenses and other current assets, total	$ 764	$ 458

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Property and Equipment, Net [Abstract]
Depreciation expenses	$ 1,622	$ 1,822	$ 1,721

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Schedule of Property and Equipment, Net [Line Items]
Property and equipment, gross	$ 15,494	$ 15,418
Less - Accumulated depreciation	(9,419)	(7,797)
Depreciated cost	6,075	7,621
Computers and software [Member]
Schedule of Property and Equipment, Net [Line Items]
Property and equipment, gross	630	620
Laboratory equipment [Member]
Schedule of Property and Equipment, Net [Line Items]
Property and equipment, gross	8,167	8,122
Furniture and office equipment [Member]
Schedule of Property and Equipment, Net [Line Items]
Property and equipment, gross	173	173
Leasehold improvements [Member]
Schedule of Property and Equipment, Net [Line Items]
Property and equipment, gross	$ 6,524	$ 6,503

Leases (Details)

Leases (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($)
Leases [Line Items]
Weighted average remaining lease term	2 years 6 months
Weighted average discount rate	10.40%
Operating lease expense	$ 1,042
Lease Agreements [Member]
Leases [Line Items]
Bank guarantees	$ 257

Leases - Schedule of Lease Liab

Leases - Schedule of Lease Liability (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Schedule of Lease Liability [Abstract]
2025	$ 999
2026	966
2027	484
Total undiscounted lease payments	2,449
Less - imputed interest	(253)
Present value of lease liabilities	$ 2,196

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Cash Flow Information Related to the Lease Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash paid for amounts included in measurement of lease liability:
Operating cash flows for operating leases	$ 900
ROU asset recognized with corresponding lease liability:
Operating leases	$ 1,522	$ 241	$ 3,528

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Schedule of Accrued Expenses And Other Current Liabilities [Abstract]
Accrued expenses	$ 1,464	$ 995
Employees and payroll accruals	1,079	958
Other liabilities	23	18
Total	$ 2,566	$ 1,971

Line of Credit Arrangement (Det

Line of Credit Arrangement (Details) - USD ($) $ / shares in Units, $ in Thousands					3 Months Ended	12 Months Ended
	Aug. 01, 2024	Mar. 29, 2023	Jul. 19, 2022	Apr. 26, 2022	Mar. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Apr. 05, 2022
Line of Credit Arrangement [Line Items]
Line of credit agreement								$ 15,000
Warrants, percentage						8%
Allocated to the warrants						$ 468
Description of loan second tranche						The proceeds allocation resulted in $2,380 allocated to the Second Tranche and $120 allocated to the warrants.
Percentage of remaining principal	60%	70%
Percentage of bears interest	12%	10%
Percentage of restructuring fee		1%
Percentage of incremental pay		3%
Repaid amount					$ 1,500
Additional paid in capital						$ 31
Restructuring fee						125
Interest paid						$ 950	$ 1,038
Percentage of credit line denominated						9.25%
Interest expenses						$ 1,651	1,685
fair value of the derivative						$ 19	$ 60
Warrant [Member]
Line of Credit Arrangement [Line Items]
Exercise price of per share (in Dollars per share)		$ 0.003				$ 3.61
Warrants purchase (in Shares)						40,000
First Tranche [Member]
Line of Credit Arrangement [Line Items]
Tranche amount				$ 10,000		$ 10,000
Period payment						317
Allocated to the warrants						$ 9,532
First Tranche [Member] | Warrant [Member]
Line of Credit Arrangement [Line Items]
Warrants purchase (in Shares)						6,491
Second Tranche [Member]
Line of Credit Arrangement [Line Items]
Tranche amount			$ 2,500			$ 2,500
Period payment						$ 85
Second Tranche [Member] | Warrant [Member]
Line of Credit Arrangement [Line Items]
Exercise price of per share (in Dollars per share)						$ 154.05
Third Tranche [Member]
Line of Credit Arrangement [Line Items]
Tranche amount						$ 2,500
Third tranche not withdrawn						$ 2,500
Minimum [Member]
Line of Credit Arrangement [Line Items]
Additional incoming funds		$ 1,500
Maximum [Member]
Line of Credit Arrangement [Line Items]
Additional incoming funds		$ 3,000
Kreos [Member]
Line of Credit Arrangement [Line Items]
Exercise price of per share (in Dollars per share)						$ 12.6
Warrants purchase (in Shares)						6,491
Claw Back [Member]
Line of Credit Arrangement [Line Items]
Line of credit agreement						$ 1,904
Interest paid						$ 4,500
First Amendment [Member]
Line of Credit Arrangement [Line Items]
Bears interest an annual rate						10%
Second Amendment [Member]
Line of Credit Arrangement [Line Items]
Bears interest an annual rate						12%
Ordinary Shares [Member]
Line of Credit Arrangement [Line Items]
Exercise price of per share (in Dollars per share)						$ 154.05

Commitments and Contingent Li_2

Commitments and Contingent Liabilities (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($)
Commitments and Contingent Liabilities [Abstract]
Aggregate amount (in Dollars)	$ 4,888
Percentage of sales	3%
Percentage of grants received	100%

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Taxes [Line Items]
Effective tax rate	(0.10%)	0.30%
Carried forward amount (in Dollars)	$ 198,927
Statutory tax rate	23%
Current tax expenses (in Dollars)	$ 42	$ 69	$ 129
Israel [Member]
Income Taxes [Line Items]
Effective tax rate	23%	23%	23%
United States of America [Member]
Income Taxes [Line Items]
Federal tax rate	21%
Minimum [Member] | United States of America [Member]
Income Taxes [Line Items]
Effective tax rate	6.50%	6.50%	6.50%
Maximum [Member] | United States of America [Member]
Income Taxes [Line Items]
Effective tax rate	11.50%	11.50%	11.50%

Income Taxes - Schedule of Loss

Income Taxes - Schedule of Loss Before Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Loss Before Taxes [Abstract]
Domestic (Israel)	$ 28,567	$ 23,348	$ 38,274
Foreign	413	448	1,154
Total	$ 28,980	$ 23,796	$ 39,428

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Deferred tax assets:
Carryforward losses	$ 45,753	$ 40,133
Research and development expenses	4,249	4,044
Operating lease liabilities	505	292
Reserves and allowances	187	207
Deferred tax assets before valuation allowance	50,694	44,676
Valuation allowance	(50,166)	(44,338)
Total deferred tax assets	528	338
Deferred tax liabilities:
Operating lease ROU assets	(528)	(338)
Total deferred tax liabilities	(528)	(338)
Net deferred tax assets, net

Shareholders_ Equity (Deficit_2

Shareholders’ Equity (Deficit) (Details) - USD ($) $ / shares in Units, $ in Thousands														3 Months Ended	12 Months Ended
	Dec. 26, 2024	Nov. 30, 2024	Aug. 06, 2024	Aug. 01, 2024	May 06, 2024	Jan. 09, 2024	Jan. 04, 2024	May 11, 2023	May 05, 2023	Mar. 31, 2023	Mar. 29, 2023	Jul. 19, 2022	Apr. 26, 2022	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Shareholders’ Equity (Deficit) [Line Items]
Aggregate offering price		$ 8,250
Total amount															$ 2	$ 2,328
Net of issuance cost																$ 92
Other offering expenses										$ 665				$ 665
Ordinary shares, Sold (in Shares)										561,967
Price per share (in Dollars per share)	$ 3.22			$ 3.61			$ 4.81			$ 12.6				$ 12.6
Public offering proceeds										$ 6,415
Fair value amount									$ 1,905						$ 2,106
Authorized share capital (in Shares)									60,000,000
Finance expenses									$ 201
Shares issued, exercised (in Shares)								345,151
Purchase common stock (in Shares)	3,386,962			2,006,226			3,143,693
Pre-funded warrants to purchase (in Shares)	1,106,868			229,231			227,619
Exercise price of per share (in Dollars per share)	$ 4			$ 3.61			$ 0.0001								$ 4.64
Warrants to purchase (in Shares)	6,740,745			1,676,588			3,371,312
Proceeds from issuance of stock	$ 13,325						$ 15,002
Net of issuance cost	1,146			$ 532			1,216
Proceeds from warrant exercises				$ 6,052			$ 18,542
Number of additional options (in Shares)					2,000,000
Share options granted (in Shares)														67,385
Stock option exercise price (in Dollars per share)														$ 23.07
Incremental value									63					$ 562
Vested option amount									$ 50					$ 307
Exercise price options (in Shares)									17,417
Weighted average grant date fair value of options granted (in Dollars per share)															$ 3.8
Expected dividend yield															0%
Unrecognized compensation costs															$ 5,599
Recognized over weighted average period															2 years 8 months 26 days
Milestone-based options (in Shares)					132,600
Warrants to purchase ordinary shares issued	2,101		$ 1,733			$ 15,248
Warrant [Member]
Shareholders’ Equity (Deficit) [Line Items]
Purchase of ordinary shares (in Shares)											345,238
Price per share (in Dollars per share)											$ 12.6
Exercise price per share (in Dollars per share)											$ 0.003				$ 3.61
Consideration amount											$ 3,987
Other offering expenses											$ 362
Public offering proceeds	$ 26,963
Minimum [Member]
Shareholders’ Equity (Deficit) [Line Items]
Authorized share capital (in Shares)									47,800,000
Maximum [Member]
Shareholders’ Equity (Deficit) [Line Items]
Authorized share capital (in Shares)									107,800,000
Share options (in Shares)					2,312,403
2012 Share Option Plan [Member]
Shareholders’ Equity (Deficit) [Line Items]
Stock option vesting period															The options granted generally have a four-year vesting period and expire ten years after the date of grant.
Stock options available for future grants (in Shares)															492,278
2012 Share Option Plan [Member] | Minimum [Member]
Shareholders’ Equity (Deficit) [Line Items]
Share options (in Shares)					312,403
Ordinary shares [Member]
Shareholders’ Equity (Deficit) [Line Items]
Purchase of ordinary shares (in Shares)															464	75,693
Inadequate of share authorized (in Shares)															167,115
Number of vote															one
Purchase Commitment [Member]
Shareholders’ Equity (Deficit) [Line Items]
Exercise price of per share (in Dollars per share)	$ 0.0001			$ 0.0001
Proceeds from issuance of stock				$ 7,536
Kreos [Member]
Shareholders’ Equity (Deficit) [Line Items]
Exercise price per share (in Dollars per share)															$ 12.6
Warrants to purchase ordinary shares issued				$ 115								$ 120	$ 468
Milestone-Based Options [Member]
Shareholders’ Equity (Deficit) [Line Items]
Milestone-based options (in Shares)					280,000
Officers [Member] | 2012 Share Option Plan [Member]
Shareholders’ Equity (Deficit) [Line Items]
Share options (in Shares)															2,312,403
Over-Allotment Option [Member]
Shareholders’ Equity (Deficit) [Line Items]
Ordinary shares, Sold (in Shares)										73,300
Private Placement [Member]
Shareholders’ Equity (Deficit) [Line Items]
Exercise price of per share (in Dollars per share)							$ 5.5

Shareholders_ Equity (Deficit_3

Shareholders’ Equity (Deficit) - Schedule of Ordinary Share Capital (Details) - Ordinary Shares [Member] - shares	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	[1]	Dec. 31, 2021	[1]
Schedule of Ordinary Share Capital [Line Items]
Ordinary shares, Authorized	107,800,000	107,800,000
Ordinary shares, Issued	10,190,904	1,653,559
Ordinary shares, Outstanding	10,190,904	1,653,559	669,605		633,093
[1] Results for the year ended December 31, 2022, have been retroactively adjusted to reflect the 1-for-30 reverse share split affected on September 18, 2023 (see Note 1b).

Shareholders_ Equity (Deficit_4

Shareholders’ Equity (Deficit) - Schedule of Status of Options to Employees (Details) - Share Option Plan [Member]	12 Months Ended
	Dec. 31, 2024 USD ($) $ / shares shares
Schedule of Status of Options to Employees [Line Items]
Number of options, Outstanding beginning balance | shares	254,437
Weighted average exercise price, Outstanding beginning balance | $ / shares	$ 22.41
Aggregate intrinsic value, Outstanding beginning balance | $
Weighted average remaining contractual life (years), Outstanding beginning balance	8 years 2 months 26 days
Number of options, Granted | shares	1,623,474
Weighted average exercise price, Granted | $ / shares	$ 4.59
Number of options, Forfeited | shares	(54,952)
Weighted average exercise price, Forfeited | $ / shares	$ 8.71
Number of options, Expired | shares	(8,408)
Weighted average exercise price, Expired | $ / shares	$ 74
Number of options, Outstanding ending balance | shares	1,814,551
Weighted average exercise price, Outstanding ending balance | $ / shares	$ 6.65
Aggregate intrinsic value, Outstanding ending balance | $
Weighted average remaining contractual life (years), Outstanding ending balance	9 years 1 month 20 days
Number of options, Exercisable options | shares	267,776
Weighted average exercise price, Exercisable options | $ / shares	$ 15.19
Aggregate intrinsic value, Exercisable options | $
Weighted average remaining contractual life (years), Exercisable options	8 years 10 days
Number of options, Vested and expected to vest | shares	1,401,951
Weighted average exercise price, Vested and expected to vest | $ / shares	$ 7.24
Aggregate intrinsic value, Vested and expected to vest | $
Weighted average remaining contractual life (years), Vested and expected to vest	9 years 1 month 20 days

Shareholders_ Equity (Deficit_5

Shareholders’ Equity (Deficit) - Schedule of Employee and Non-Employee Share Options at the Grant Dates (Details) - Black-Scholes [Member]	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Employee and Non-Employee Share Options at the Grant Dates [Line Items]
Dividend yield (%)	0%	0%	0%
Minimum [Member]
Schedule of Employee and Non-Employee Share Options at the Grant Dates [Line Items]
Expected volatility (%)	97.10%	92.59%	70.45%
Risk-free interest rate (%)	3.74%	3.38%	1.81%
Expected term (in years)	6 months	5 years 3 months 18 days	1 year 2 months 12 days
Maximum [Member]
Schedule of Employee and Non-Employee Share Options at the Grant Dates [Line Items]
Expected volatility (%)	103%	95.67%	93.85%
Risk-free interest rate (%)	5.06%	4.71%	4.31%
Expected term (in years)	6 years 1 month 6 days	6 years 1 month 6 days	6 years 2 months 12 days

Shareholders_ Equity (Deficit_6

Shareholders’ Equity (Deficit) - Schedule of Share-Based Compensation Expense Recognized (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Share-Based Compensation Expense Recognized [Line Items]
Total share-based compensation expense	$ 2,824	$ 3,391	$ 4,307
Research and development [Member]
Schedule of Share-Based Compensation Expense Recognized [Line Items]
Total share-based compensation expense	1,539	1,791	2,081
Marketing and business development [Member]
Schedule of Share-Based Compensation Expense Recognized [Line Items]
Total share-based compensation expense	291	339	383
General and administrative [Member]
Schedule of Share-Based Compensation Expense Recognized [Line Items]
Total share-based compensation expense	$ 994	$ 1,261	$ 1,843

Shareholders_ Equity (Deficit_7

Shareholders’ Equity (Deficit) - Schedule of Relative Fair Value of the Warrants to Purchase Ordinary Shares Issued (Details)	Dec. 26, 2024	Aug. 06, 2024	Jan. 09, 2024	Aug. 01, 2022	Jul. 19, 2022	Apr. 26, 2022
Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of the warrants to purchase Ordinary shares issued	2.85	3.5	6.89	3.65	153.6	148.8
Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of the warrants to purchase Ordinary shares issued	4	3.61	5.5	3.61	154.05	154.05
Expected Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of the warrants to purchase Ordinary shares issued	77.48			88	60.57	60.81
Expected Volatility [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of the warrants to purchase Ordinary shares issued		95	117.4
Expected Volatility [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of the warrants to purchase Ordinary shares issued		129	134
Adjustment to Risk-Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of the warrants to purchase Ordinary shares issued	4.22			3.89	3.07	2.84
Adjustment to Risk-Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of the warrants to purchase Ordinary shares issued		3.91	4.27
Adjustment to Risk-Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of the warrants to purchase Ordinary shares issued		4.98	5.96
Dividend Yield [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of the warrants to purchase Ordinary shares issued
Risk-Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of the warrants to purchase Ordinary shares issued	4.31			3.89	3.11	2.88
Risk-Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of the warrants to purchase Ordinary shares issued		3.99	4.36
Risk-Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of the warrants to purchase Ordinary shares issued		5.11	5.08
Expected Life [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant expected life	6 months			7 years	6 years 8 months 19 days	6 years 11 months 8 days
Expected Life [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant expected life		4 months 24 days	8 months 4 days
Expected Life [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant expected life		2 years	2 years

Shareholders_ Equity (Deficit_8

Shareholders’ Equity (Deficit) - Schedule of Warrants Exercisable Into Ordinary Shares (Details)	12 Months Ended
	Dec. 31, 2024 $ / shares shares
Schedule of Warrants Exercisable Into Ordinary Shares [Line Items]
Warrants outstanding	13,398,854
Warrants exercisable	13,398,854
April 2022 [Member]
Schedule of Warrants Exercisable Into Ordinary Shares [Line Items]
Warrants outstanding	5,193
Average Exercise price per share (in Dollars per share) | $ / shares	$ 12.6
Warrants exercisable	5,193
Exercisable through	April 2029
July 2022 [Member]
Schedule of Warrants Exercisable Into Ordinary Shares [Line Items]
Warrants outstanding	1,298
Average Exercise price per share (in Dollars per share) | $ / shares	$ 12.6
Warrants exercisable	1,298
Exercisable through	April 2029
January 2024 [Member]
Schedule of Warrants Exercisable Into Ordinary Shares [Line Items]
Warrants outstanding	3,371,312
Average Exercise price per share (in Dollars per share) | $ / shares	$ 5.5
Warrants exercisable	3,371,312
Exercisable through	January 2026 *)	[1]
January 2024 [Member]
Schedule of Warrants Exercisable Into Ordinary Shares [Line Items]
Warrants outstanding	227,619
Average Exercise price per share (in Dollars per share) | $ / shares	$ 0.0001
Warrants exercisable	227,619
Exercisable through	No maturity date *)	[1]
August 2024 [Member]
Schedule of Warrants Exercisable Into Ordinary Shares [Line Items]
Warrants outstanding	1,676,588
Average Exercise price per share (in Dollars per share) | $ / shares	$ 3.61
Warrants exercisable	1,676,588
Exercisable through	August 2026 *)	[1]
August 2024 [Member]
Schedule of Warrants Exercisable Into Ordinary Shares [Line Items]
Warrants outstanding	229,231
Average Exercise price per share (in Dollars per share) | $ / shares	$ 0.0001
Warrants exercisable	229,231
Exercisable through	No maturity date *)	[1]
August 2024 [Member]
Schedule of Warrants Exercisable Into Ordinary Shares [Line Items]
Warrants outstanding	40,000
Average Exercise price per share (in Dollars per share) | $ / shares	$ 3.61
Warrants exercisable	40,000
Exercisable through	August 2031
December 2024 [Member]
Schedule of Warrants Exercisable Into Ordinary Shares [Line Items]
Warrants outstanding	6,740,745
Average Exercise price per share (in Dollars per share) | $ / shares	$ 4
Warrants exercisable	6,740,745
Exercisable through	September 2025 *)	[1]
December 2024 [Member]
Schedule of Warrants Exercisable Into Ordinary Shares [Line Items]
Warrants outstanding	1,106,868
Average Exercise price per share (in Dollars per share) | $ / shares	$ 0.0001
Warrants exercisable	1,106,868
Exercisable through	No maturity date *)	[1]
[1]See Note 10d.

Financial Expenses, Net - Sched

Financial Expenses, Net - Schedule of Financial Expenses, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Financial expenses:
Financial expenses from credit line and derivative	$ 1,510	$ 1,618	$ 1,023
Other financial expenses	15	93	316
Total financial expenses	1,525	1,711	1,339
Financial income:
Foreign currency transaction gains, net	(113)	(33)	(532)
Interest income from bank deposits	(442)	(548)	(267)
Other financial income	(19)
Remeasurement of warrants		(201)
Total financial income	(574)	(782)	(799)
Total financial expense, net	$ 951	$ 929	$ 540

Basic and Diluted Net Loss Pe_3

Basic and Diluted Net Loss Per Share - Schedule of Basic and Diluted Loss Per Ordinary Share (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Basic loss per share:
Net loss		$ 29,022	$ 23,865	$ 39,557
Shares used in computation:
Weighted-average shares of Ordinary shares outstanding	[1]	5,912,890	1,404,368	647,556
Basic loss per share	[1]	$ 4.91	$ 16.99	$ 61.09
Diluted loss per share:
Net loss		$ 29,022	$ 24,066	$ 39,557
Shares used in computation:
Weighted-average shares of Ordinary shares outstanding	[1]	5,912,890	1,421,308	647,556
Diluted loss per share	[1]	$ 4.91	$ 16.93	$ 61.09
[1] Results for the year ended December 31, 2022, have been retroactively adjusted to reflect the 1-for-30 reverse share split affected on September 18, 2023 (see Note 1b).

Basic and Diluted Net Loss Pe_4

Basic and Diluted Net Loss Per Share - Schedule of Diluted Net Loss Per Share Attributable to Ordinary Shareholders (Details) - shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Diluted Net Loss Per Share Attributable to Ordinary Shareholders [Line Items]
Total	13,666,630	78,544	96,689
Ordinary share options [Member]
Schedule of Diluted Net Loss Per Share Attributable to Ordinary Shareholders [Line Items]
Total	267,776	71,456	82,914
Warrants [Member]
Schedule of Diluted Net Loss Per Share Attributable to Ordinary Shareholders [Line Items]
Total	13,398,854	7,088	13,775

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)			12 Months Ended
	Jul. 31, 2025	Jan. 06, 2025	Dec. 31, 2024
Subsequent Event [Line Items]
Restructuring fee (in Dollars)			$ 125,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Percentage of principal and interest repayments		60%
Forecast [Member]
Subsequent Event [Line Items]
Restructuring fee (in Dollars)	$ 160
Forecast [Member] | Minimum [Member]
Subsequent Event [Line Items]
Percentage of loan payment	5%
Forecast [Member] | Maximum [Member]
Subsequent Event [Line Items]
Percentage of loan payment	7%